Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

BRENDA Home
show all | hide all No of entries

Information on EC 3.4.23.15 - renin and Organism(s) Homo sapiens and UniProt Accession P00797

for references in articles please use BRENDA:EC3.4.23.15
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EC Tree
     3 Hydrolases
         3.4 Acting on peptide bonds (peptidases)
             3.4.23 Aspartic endopeptidases
                3.4.23.15 renin
Specify your search results
Select one or more organisms in this record: ?
This record set is specific for:
Homo sapiens
UNIPROT: P00797 not found.
Show additional data
Do not include text mining results
Include (text mining) results
Include results (AMENDA + additional results, but less precise)
Word Map
The taxonomic range for the selected organisms is: Homo sapiens
The enzyme appears in selected viruses and cellular organisms
Reaction Schemes
cleavage of Leu-/- bond in angiotensinogen to generate angiotensin I
Synonyms
renin, prorenin, angiotensinogenase, angiotensin-forming enzyme, more
SYNONYM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
angiotensin-forming enzyme
-
-
-
-
angiotensinogenase
-
-
-
-
prorenin
-
proenzyme
CAS REGISTRY NUMBER
COMMENTARY hide
9015-94-5
-
SUBSTRATE
PRODUCT                       
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
angiotensinogen + H2O
angiotensin I + angiotensinogen propeptide
show the reaction diagram
Arg-Glu(EDANS)-Ile-His-Pro-Phe-His-Leu-Val-Ile-His-Thr-Lys(DABCYL)-Arg + H2O
?
show the reaction diagram
-
-
-
?
DABCYL-c-Abu-Ile-His-Pro-Phe-His-Leu-Val-Ile-His-Thr-EDANS + H2O
?
show the reaction diagram
-
-
-
?
4-(4-dimethylaminophenylazo)benzoic acid-IHPFHLVIHT-5-[(e-amino-ethyl)amino]naphthalene-1-sulfonic acid + H2O
4-(4-dimethylaminophenylazo)benzoic acid-IHPFHL + VIHT-5-[(e-amino-ethyl)amino]naphthalene-1-sulfonic acid
show the reaction diagram
-
fluorogenic peptide
-
-
?
aliskiren + H2O
?
show the reaction diagram
-
-
-
-
?
angiotensinogen + H2O
?
show the reaction diagram
angiotensinogen + H2O
angiotensin I + ?
show the reaction diagram
angiotensinogen + H2O
angiotensin I + angiotensinogen propeptide
show the reaction diagram
Arg-Glu(5-[(2-aminoethyl)amino]-naphthalene-1-sulfonic acid)-Ile-His-Pro-Phe-His-Leu-Val-Ile-His-Thr-Lys(4-(4-dimethylaminophenylazo)-benzoic acid)-Arg + H2O
?
show the reaction diagram
-
commercial renin peptide substrate 1
-
-
?
megsin + H2O
?
show the reaction diagram
-
the protein which carries a naturally occurring His-Pro-Phe sequence, is cleaved by renin at the C-terminal side of the His-Pro-Phe-Leu-Phe sequence
-
-
?
N-methylanthranyl-Ile-His-Pro-Phe-His-Leu-Val-Ile-Thr-His-Lys-2,4-dinitrophenyl-D-Arg-D-Arg-NH2 + H2O
N-methylanthranyl-Ile-His-Pro-Phe-His-Leu + Val-Ile-Thr-His-Lys-2,4-dinitrophenyl-D-Arg-D-Arg-NH2
show the reaction diagram
-
-
-
-
?
recombinant ovine angiotensinogen from CHO cells + H2O
angiotensin I + angiotensinogen propeptide
show the reaction diagram
-
-
-
-
?
recombinant ovine angiotensinogen from Escherichia coli + H2O
angiotensin I + angiotensinogen propeptide
show the reaction diagram
-
-
-
-
?
additional information
?
-
NATURAL SUBSTRATE
NATURAL PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
angiotensinogen + H2O
angiotensin I + angiotensinogen propeptide
show the reaction diagram
-
-
-
?
angiotensinogen + H2O
?
show the reaction diagram
angiotensinogen + H2O
angiotensin I + angiotensinogen propeptide
show the reaction diagram
additional information
?
-
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(2R)-1-methoxy-3-([(3S,4R,5R)-4-(4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl)-5-[(4-methoxynaphthalen-2-yl)methoxy]piperidin-3-yl]oxy)propan-2-ol
-
(3R)-3-[(1S)-1-(2-chlorophenyl)-1-hydroxy-5-methoxypentyl]-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]piperidine-1-carboxamide
-
(3R)-3-[(1S)-1-(3-bromophenyl)-1-hydroxy-5-methoxypentyl]-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]piperidine-1-carboxamide
-
(3R)-3-[(1S)-1-(3-chloro-2-fluorophenyl)-1-hydroxy-5-methoxypentyl]-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]piperidine-1-carboxamide
-
(3R)-3-[(1S)-1-(3-chloro-5-fluorophenyl)-1-hydroxy-5-methoxypentyl]-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]piperidine-1-carboxamide
-
(3R)-3-[(1S)-1-(3-chlorophenyl)-1,5-dihydroxypentyl]-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]piperidine-1-carboxamide
-
(3R)-3-[(1S)-1-(3-chlorophenyl)-1-hydroxy-5-methoxypentyl]-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]piperidine-1-carboxamide
-
(3R)-3-[(1S)-1-(3-chlorophenyl)-1-hydroxy-5-methoxypentyl]-N-[(2S)-1-cyclohexyl-3-[(2,2,2-trifluoroethyl)amino]propan-2-yl]piperidine-1-carboxamide
-
(3R)-3-[(1S)-1-(3-cyanophenyl)-1-hydroxy-5-methoxypentyl]-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]piperidine-1-carboxamide
-
(3R)-3-[(R)-(3-chloro-2-fluorophenyl)(3-methoxypropoxy)methyl]-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]piperidine-1-carboxamide
-
(3R)-3-[(R)-(3-chlorophenyl)(3-ethoxypropoxy)methyl]-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]piperidine-1-carboxamide
-
(3R)-3-[(R)-(3-chlorophenyl)(3-hydroxypropoxy)methyl]-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]piperidine-1-carboxamide
-
(3R)-N-[(2S)-1-amino-3-cyclohexylpropan-2-yl]-3-[(1S)-1-hydroxy-5-methoxy-1-phenylpentyl]piperidine-1-carboxamide
-
(3R)-N-[(2S)-1-amino-3-cyclohexylpropan-2-yl]-3-[(1S)-5-ethoxy-1-hydroxy-1-phenylpentyl]piperidine-1-carboxamide
-
(3R)-N-[(2S)-1-amino-3-cyclohexylpropan-2-yl]-3-[(R)-(3-chlorophenyl)(3-ethoxypropoxy)methyl]piperidine-1-carboxamide
-
(3R)-N-[(2S)-1-amino-3-cyclohexylpropan-2-yl]-3-[(R)-(3-ethoxypropoxy)(phenyl)methyl]piperidine-1-carboxamide
-
(3R)-N-[(2S)-1-amino-3-cyclohexylpropan-2-yl]-3-[(R)-(3-methoxypropoxy)(phenyl)methyl]piperidine-1-carboxamide
-
(3R)-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]-3-[(1S)-1-(2,3-difluorophenyl)-1-hydroxy-5-methoxypentyl]piperidine-1-carboxamide
-
(3R)-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]-3-[(1S)-1-(2-fluoro-5-methylphenyl)-1-hydroxy-5-methoxypentyl]piperidine-1-carboxamide
-
(3R)-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]-3-[(1S)-1-(2-fluorophenyl)-1-hydroxy-5-methoxypentyl]piperidine-1-carboxamide
-
(3R)-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]-3-[(1S)-1-(3-ethylphenyl)-1-hydroxy-5-methoxypentyl]piperidine-1-carboxamide
-
(3R)-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]-3-[(1S)-1-(3-fluorophenyl)-1-hydroxy-5-methoxypentyl]piperidine-1-carboxamide
-
(3R)-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]-3-[(1S)-1-hydroxy-5-methoxy-1-(3-methoxyphenyl)pentyl]piperidine-1-carboxamide
-
(3R)-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]-3-[(1S)-1-hydroxy-5-methoxy-1-(3-methylphenyl)pentyl]piperidine-1-carboxamide
-
(3R)-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]-3-[(1S)-1-hydroxy-5-methoxy-1-phenylpentyl]piperidine-1-carboxamide
-
(3R)-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]-3-[(1S)-1-hydroxy-5-methoxy-1-[3-(trifluoromethoxy)phenyl]pentyl]piperidine-1-carboxamide
-
(3R)-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]-3-[(1S)-1-hydroxy-5-methoxy-1-[3-(trifluoromethyl)phenyl]pentyl]piperidine-1-carboxamide
-
(3R)-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]-3-[(1S)-5-ethoxy-1-hydroxy-1-phenylpentyl]piperidine-1-carboxamide
-
(3R)-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]-3-[(R)-(2,3-dichlorophenyl)(3-ethoxypropoxy)methyl]piperidine-1-carboxamide
-
(3R)-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]-3-[(R)-(2,3-dichlorophenyl)(3-methoxypropoxy)methyl]piperidine-1-carboxamide
-
(3R)-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]-3-[(R)-(3-ethoxypropoxy)(3-fluorophenyl)methyl]piperidine-1-carboxamide
-
(3R)-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]-3-[(R)-(3-ethoxypropoxy)(phenyl)methyl]piperidine-1-carboxamide
-
(3R)-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]-3-[(R)-(3-fluorophenyl)(3-methoxypropoxy)methyl]piperidine-1-carboxamide
-
(3R)-N-[(2S)-1-[(chloromethyl)amino]-3-cyclohexylpropan-2-yl]-3-[(1S)-1-(3-chlorophenyl)-1-hydroxy-5-methoxypentyl]piperidine-1-carboxamide
-
3-(5-amino-5-oxopentanoyl)-7-[4-[3-(2-bromo-5-fluorophenoxy)propyl]phenyl]-N-(2-chlorobenzyl)-N-cyclopropyl-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxamide
-
6-(2,4-diamino-6-ethylpyrimidin-5-yl)-2-(3,5-difluorophenyl)-4-(3-methoxypropyl)-2-methyl-2H-1,4-benzoxazin-3(4H)-one
-
7-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-N-cyclopropyl-N-(2,3-dichlorobenzyl)-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxamide
the (+)- and (-)-enantiomers are almost equally potent as renin inhibotrs in buffer and in plasma. crystallization data
aliskiren
-
N-cyclopropyl-7-[4-[3-(2,6-dichloro-4-methylphenoxy)propyl]phenyl]-N-(2,3-dimethylbenzyl)-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxamide
-
Pro-Arg-Tyr
mixed-type inhibition
remikiren
RO 42-5892
Trp-Gly
mixed-type inhibition
(1R,5S)-3-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-N-cyclopropyl-N-(2,3-dichlorobenzyl)-8-azabicyclo[3.2.1]oct-2-ene-2-carboxamide
-
-
(1S)-7-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-N-cyclopropyl-N-(2,3-dichlorobenzyl)-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxamide
-
-
(1S)-7-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-N-cyclopropyl-N-(2,3-dichlorobenzyl)-3-oxa-9-azabicyclo[3.3.1]non-6-ene-6-carboxamide
-
-
(1S)-7-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-N-cyclopropyl-N-(2,3-dichlorobenzyl)-3-thia-9-azabicyclo[3.3.1]non-6-ene-6-carboxamide 3,3-dioxide
-
-
(1S)-7-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-N-cyclopropyl-N-(2,3-dichlorobenzyl)-3-thia-9-azabicyclo[3.3.1]non-6-ene-6-carboxamide 3-oxide
-
-
(1S)-7-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-N-cyclopropyl-N-(3-methoxy-2-methylbenzyl)-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxamide
-
-
(1S)-7-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-N-cyclopropyl-N-(3-methoxy-2-methylbenzyl)-3-oxa-9-azabicyclo[3.3.1]non-6-ene-6-carboxamide
-
-
(1S)-7-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-N-cyclopropyl-N-(3-methoxy-2-methylbenzyl)-3-thia-9-azabicyclo[3.3.1]non-6-ene-6-carboxamide 3,3-dioxide
-
-
(1S)-7-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-N-cyclopropyl-N-(3-methoxy-2-methylbenzyl)-3-thia-9-azabicyclo[3.3.1]non-6-ene-6-carboxamide 3-oxide
-
-
(2R)-3-amino-N-cyclopropyl-2-[4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl]-N-[3-(2-methoxyethoxy)-5-(3-methoxypropyl)benzyl]propanamide
-
-
(2R)-6-(2,4-diamino-6-ethylpyrimidin-5-yl)-4-(3-methoxypropyl)-2-methyl-2H-1,4-benzoxazin-3(4H)-one
-
-
(2R,4S,5S)-5-amino-N-butyl-4-hydroxy-6-[[(4-methoxyphenyl)sulfonyl](propan-2-yl)amino]-2-methylhexanamide
-
-
(2R,4S,5S)-5-amino-N-butyl-4-hydroxy-6-[[4-methoxy-3-(3-methoxypropoxy)benzyl](propan-2-yl)amino]-2-methylhexanamide
-
-
(2R,4S,5S)-5-amino-N-butyl-4-hydroxy-6-[[[4-methoxy-3-(3-methoxypropoxy)phenyl]sulfonyl](propan-2-yl)amino]-2-methylhexanamide
-
-
(2R,4S,5S,7S)-5-amino-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2,8-dimethyl-N-(2-methyl-2-morpholin-4-ylpropyl)nonanamide
-
-
(2R,4S,5S,7S)-5-amino-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2,8-dimethyl-N-(2-morpholin-4-ylethyl)nonanamide
-
-
(2R,4S,5S,7S)-5-amino-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2,8-dimethyl-N-(2-piperidin-1-ylethyl)nonanamide
-
-
(2R,4S,5S,7S)-5-amino-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2,8-dimethyl-N-(2-pyridin-2-ylethyl)nonanamide
-
-
(2R,4S,5S,7S)-5-amino-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2,8-dimethyl-N-(2-thiomorpholin-4-ylethyl)nonanamide
-
-
(2R,4S,5S,7S)-5-amino-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2,8-dimethyl-N-(3-morpholin-4-ylpropyl)nonanamide
-
-
(2R,4S,5S,7S)-5-amino-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2,8-dimethyl-N-(4-morpholin-4-yl-4-oxobutyl)nonanamide
-
-
(2R,4S,5S,7S)-5-amino-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2,8-dimethyl-N-[3-(1H-tetrazol-5-yl)propyl]nonanamide
-
-
(2R,4S,5S,7S)-5-amino-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2,8-dimethyl-N-[3-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]nonanamide
-
-
(2R,4S,5S,7S)-5-amino-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2,8-dimethyl-N-[4-(methylamino)-4-oxobutyl]nonanamide
-
-
(2R,4S,5S,7S)-5-amino-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2-methyl-N-[2-(piperidin-1-yl)ethyl]nonanamide
-
-
(2R,4S,5S,7S)-5-amino-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2-methyl-N-[2-(pyridin-2-yl)ethyl]nonanamide
-
-
(2R,4S,5S,7S)-5-amino-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2-methyl-N-[3-(1H-tetrazol-5-yl)propyl]nonanamide
-
-
(2R,4S,5S,7S)-5-amino-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2-methyl-N-[3-(morpholin-4-yl)propyl]nonanamide
-
-
(2R,4S,5S,7S)-5-amino-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-N-(3-methoxypropyl)-2,8-dimethylnonanamide
-
-
(2R,4S,5S,7S)-5-amino-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-N-[2-(4-methoxypiperidin-1-yl)ethyl]-2,8-dimethylnonanamide
-
-
(2R,4S,5S,7S)-5-amino-4-hydroxy-N-(3-hydroxypropyl)-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2,8-dimethylnonanamide
-
-
(2R,4S,5S,7S)-5-amino-4-hydroxy-N-(4-hydroxybutyl)-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2,8-dimethylnonanamide
-
-
(2R,4S,5S,7S)-5-amino-4-hydroxy-N-[(4-hydroxypiperidin-1-yl)methyl]-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2-methylnonanamide
-
-
(2R,4S,5S,7S)-5-amino-4-hydroxy-N-[2-(4-hydroxypiperidin-1-yl)ethyl]-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2,8-dimethylnonanamide
-
-
(2R,4S,5S,7S)-5-amino-4-hydroxy-N-[3-(1H-imidazol-4-yl)propyl]-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2,8-dimethylnonanamide
-
-
(2R,4S,5S,7S)-5-amino-4-hydroxy-N-[4-[(2-methoxyethyl)amino]-4-oxobutyl]-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2,8-dimethylnonanamide
-
-
(2R,4S,5S,7S)-5-amino-7-[3-(2-amino-2-oxoethoxy)-4-methoxybenzyl]-N-butyl-4-hydroxy-2,8-dimethylnonanamide
-
-
(2R,4S,5S,7S)-5-amino-7-[3-(2-amino-2-oxoethoxy)-4-methoxybenzyl]-N-butyl-4-hydroxy-2-methylnonanamide
-
-
(2R,4S,5S,7S)-5-amino-7-[3-(2-amino-2-oxoethoxy)-4-tert-butylbenzyl]-N-butyl-4-hydroxy-2-methylnonanamide
-
-
(2R,4S,5S,7S)-5-amino-7-[3-(benzyloxy)-4-methoxybenzyl]-N-butyl-4-hydroxy-2,8-dimethylnonanamide
-
-
(2R,4S,5S,7S)-5-amino-N-(2-aminoethyl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2-methylnonanamide
-
-
(2R,4S,5S,7S)-5-amino-N-(3-amino-3-oxopropyl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2,8-dimethylnonanamide
-
-
(2R,4S,5S,7S)-5-amino-N-(3-amino-3-oxopropyl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2-methylnonanamide
-
-
(2R,4S,5S,7S)-5-amino-N-(3-aminopropyl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2,8-dimethylnonanamide
-
-
(2R,4S,5S,7S)-5-amino-N-(3-cyanopropyl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2,8-dimethylnonanamide
-
-
(2R,4S,5S,7S)-5-amino-N-(4-amino-4-oxobutyl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2,8-dimethylnonanamide
-
-
(2R,4S,5S,7S)-5-amino-N-(4-amino-4-oxobutyl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2-methylnonanamide
-
-
(2R,4S,5S,7S)-5-amino-N-(5-amino-5-oxopentyl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2,8-dimethylnonanamide
-
-
(2R,4S,5S,7S)-5-amino-N-(5-amino-5-oxopentyl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2-methylnonanamide
-
-
(2R,4S,5S,7S)-5-amino-N-butyl-4-hydroxy-7-[3-(3-hydroxypropoxy)-4-methoxybenzyl]-2,8-dimethylnonanamide
-
-
(2R,4S,5S,7S)-5-amino-N-butyl-4-hydroxy-7-[3-(3-hydroxypropoxy)-4-methoxybenzyl]-2-methylnonanamide
-
-
(2R,4S,5S,7S)-5-amino-N-butyl-4-hydroxy-7-[4-methoxy-3-(2-methoxyethoxy)benzyl]-2,8-dimethylnonanamide
-
-
(2R,4S,5S,7S)-5-amino-N-butyl-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2,8-dimethylnonanamide
-
-
(2R,4S,5S,7S)-5-amino-N-butyl-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2-methylnonanamide
-
-
(2R,4S,5S,7S)-5-amino-N-butyl-4-hydroxy-7-[4-methoxy-3-(4-methoxybutoxy)benzyl]-2,8-dimethylnonanamide
-
-
(2R,4S,5S,7S)-5-amino-N-butyl-4-hydroxy-7-[4-methoxy-3-(pentyloxy)benzyl]-2,8-dimethylnonanamide
-
-
(2R,4S,5S,7S)-5-amino-N-butyl-4-hydroxy-7-[4-methoxy-3-(pentyloxy)benzyl]-2-methylnonanamide
-
-
(2R,4S,5S,7S)-5-amino-N-butyl-4-hydroxy-7-[4-methoxy-3-(pyridin-4-ylmethoxy)benzyl]-2,8-dimethylnonanamide
-
-
(2R,4S,5S,7S)-5-amino-N-butyl-4-hydroxy-7-[4-methoxy-3-[(methylsulfonyl)methoxy]benzyl]-2,8-dimethylnonanamide
-
-
(2R,4S,5S,7S)-5-amino-N-butyl-4-hydroxy-7-[4-methoxy-3-[2-(2-methoxyethoxy)ethoxy]benzyl]-2,8-dimethylnonanamide
-
-
(2R,4S,5S,7S)-5-amino-N-butyl-4-hydroxy-7-[4-methoxy-3-[2-(2-methoxyethoxy)ethoxy]benzyl]-2-methylnonanamide
-
-
(2R,4S,5S,7S)-5-amino-N-butyl-4-hydroxy-7-[4-methoxy-3-[2-(methylamino)-2-oxoethoxy]benzyl]-2,8-dimethylnonanamide
-
-
(2R,4S,5S,7S)-5-amino-N-butyl-4-hydroxy-7-[4-methoxy-3-[2-(methylamino)-2-oxoethoxy]benzyl]-2-methylnonanamide
-
-
(2R,4S,5S,7S)-5-amino-N-butyl-7-[3-(2-ethoxyethoxy)-4-methoxybenzyl]-4-hydroxy-2,8-dimethylnonanamide
-
-
(2R,4S,5S,7S)-5-amino-N-butyl-7-[3-(3-ethoxypropoxy)-4-methoxybenzyl]-4-hydroxy-2,8-dimethylnonanamide
-
-
(2R,4S,5S,7S)-5-amino-N-butyl-7-[3-[2,2-dimethyl-3-(methylamino)-3-oxopropoxy]-4-methoxybenzyl]-4-hydroxy-2-methylnonanamide
-
-
(2R,4S,5S,7S)-5-amino-N-[2-(1,1-dioxidothiomorpholin-4-yl)ethyl]-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2,8-dimethylnonanamide
-
-
(2R,4S,5S,7S)-5-amino-N-[2-(dimethylamino)ethyl]-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2,8-dimethylnonanamide
-
-
(2R,4S,5S,7S)-5-amino-N-[2-(dimethylamino)ethyl]-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2-methylnonanamide
-
-
(2R,4S,5S,7S)-5-amino-N-[2-(dimethylsulfamoyl)ethyl]-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2,8-dimethylnonanamide
-
-
(2R,4S,5S,7S)-5-amino-N-[2-(ethylsulfonyl)ethyl]-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2,8-dimethylnonanamide
-
-
(2R,4S,5S,7S)-5-amino-N-[2-(tert-butylsulfonyl)ethyl]-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2,8-dimethylnonanamide
-
-
(2R,4S,5S,7S)-5-amino-N-[2-[(2R,6S)-2,6-dimethylmorpholin-4-yl]ethyl]-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2,8-dimethylnonanamide
-
-
(2R,4S,5S,7S)-N-[2-(acetylamino)ethyl]-5-amino-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2,8-dimethylnonanamide
-
-
(2S)-6-(2,4-diamino-6-ethylpyrimidin-5-yl)-2-(3,5-difluorophenyl)-4-(3-methoxypropyl)-2-methyl-2H-1,4-benzoxazin-3(4H)-one
-
-
(2S,4S,5S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-6-[[4-methoxy-3-(3-methoxypropoxy)benzyl](propan-2-yl)amino]-2-(propan-2-yl)hexanamide
-
-
(2S,4S,5S,7S)-5-amino-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-N-[2-methyl-1-(morpholin-4-yl)propan-2-yl]-2-(propan-2-yl)nonanamide
-
-
(2S,4S,5S,7S)-5-amino-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-N-[2-methyl-3-(methylamino)-3-oxopropyl]-2-(propan-2-yl)nonanamide
-
-
(2S,4S,5S,7S)-5-amino-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-N-[4-(methylamino)-4-oxobutyl]-2-(propan-2-yl)nonanamide
-
-
(2S,4S,5S,7S)-5-amino-N-(1-amino-1-oxopropan-2-yl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2-(propan-2-yl)nonanamide
-
-
(2S,4S,5S,7S)-5-amino-N-(1-amino-2-methyl-1-oxopropan-2-yl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2-(propan-2-yl)nonanamide
-
-
(2S,4S,5S,7S)-5-amino-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2-(propan-2-yl)nonanamide
-
-
(2S,4S,5S,7S)-5-amino-N-(2-amino-2-oxoethyl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2-(propan-2-yl)nonanamide
-
-
(2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2-(propan-2-yl)nonanamide
-
-
(2S,4S,5S,7S)-5-amino-N-(3-amino-2-methyl-3-oxopropyl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2-(propan-2-yl)nonanamide
-
-
(2S,4S,5S,7S)-5-amino-N-(4-amino-4-oxobutan-2-yl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2-(propan-2-yl)nonanamide
-
-
(2S,4S,5S,7S)-5-amino-N-(4-amino-4-oxobutyl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2-(propan-2-yl)nonanamide
-
-
(2S,4S,5S,7S)-5-amino-N-[2,2-dimethyl-3-(methylamino)-3-oxopropyl]-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2-(propan-2-yl)nonanamide
-
-
(3R)-3-[(1S)-1-(3-chlorophenyl)-1,5-dihydroxypentyl]-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]piperidine-1-carboxamide
-
-
(3R)-3-[(1S)-1-(3-chlorophenyl)-1-hydroxy-4-(propanoylamino)butyl]-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]piperidine-1-carboxamide
-
-
(3R)-3-[(1S)-1-(3-chlorophenyl)-1-hydroxy-4-(sulfamoylamino)butyl]-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]piperidine-1-carboxamide
-
-
(3R)-3-[(1S)-1-(3-chlorophenyl)-1-hydroxy-4-[(methylcarbamoyl)amino]butyl]-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]piperidine-1-carboxamide
-
-
(3R)-3-[(1S)-1-(3-chlorophenyl)-1-hydroxy-4-[(methylsulfonyl)amino]butyl]-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]piperidine-1-carboxamide
-
-
(3R)-3-[(1S)-1-(3-chlorophenyl)-1-hydroxy-5-methoxypentyl]-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]piperidine-1-carboxamide
-
-
(3R)-3-[(1S)-1-(3-chlorophenyl)-4-[(cyclopropylcarbonyl)amino]-1-hydroxybutyl]-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]piperidine-1-carboxamide
-
-
(3R)-3-[(1S)-1-(3-chlorophenyl)-4-[(dimethylcarbamoyl)amino]-1-hydroxybutyl]-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]piperidine-1-carboxamide
-
-
(3R)-3-[(1S)-4-(acetylamino)-1-(3-chlorophenyl)-1-hydroxybutyl]-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]piperidine-1-carboxamide
-
-
(3R)-3-[(1S)-4-(butanoylamino)-1-(3-chlorophenyl)-1-hydroxybutyl]-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]piperidine-1-carboxamide
-
-
(3R)-3-[(1S)-4-(carbamoylamino)-1-(3-chlorophenyl)-1-hydroxybutyl]-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]piperidine-1-carboxamide
-
-
(3R)-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]-3-[(R)-(3-ethoxypropoxy)(phenyl)methyl]piperidine-1-carboxamide
-
-
(5R)-3-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-N-cyclopropyl-N-(2,3-dichlorobenzyl)-8-azabicyclo[3.2.1]oct-2-ene-2-carboxamide
-
-
(5R)-3-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-N-cyclopropyl-N-(2,3-dichlorobenzyl)-9-azabicyclo[3.3.1]non-2-ene-2-carboxamide
-
-
(5R)-3-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-N-cyclopropyl-N-(3-methoxy-2-methylbenzyl)-8-azabicyclo[3.2.1]oct-2-ene-2-carboxamide
-
-
(5R)-3-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-N-cyclopropyl-N-(3-methoxy-2-methylbenzyl)-9-azabicyclo[3.3.1]non-2-ene-2-carboxamide
-
-
2'-O-beta-D-glucopyranosyl momordin Ic
-
-
2'-O-beta-D-glucopyranosyl momordin IIc
-
-
2-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]benzyl]-N-cyclopropyl-N-(2,3-dichlorobenzyl)-3-(methylamino)propanamide
-
-
3-(benzylamino)-2-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]benzyl]-N-cyclopropyl-N-(2,3-dichlorobenzyl)propanamide
-
-
3-amino-2-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]benzyl]-N-cyclopropyl-N-(2,3-dichlorobenzyl)-2-methylpropanamide
-
-
3-amino-2-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]benzyl]-N-cyclopropyl-N-(2,3-dichlorobenzyl)propanamide
-
-
3-amino-N-cyclopropyl-N-(2,3-dichlorobenzyl)-2-[4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl]propanamide
-
-
3-amino-N-cyclopropyl-N-[2,3-dichloro-5-(3-methoxypropyl)benzyl]-2-[4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl]propanamide
-
-
3-amino-N-[2-chloro-5-(2-cyanoethyl)benzyl]-N-cyclopropyl-2-[4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl]propanamide
-
-
3-amino-N-[2-chloro-5-(3-cyanopropyl)benzyl]-N-cyclopropyl-2-[4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl]propanamide
-
-
3-amino-N-[2-chloro-5-(3-hydroxypropyl)benzyl]-N-cyclopropyl-2-[4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl]propanamide
-
-
3-amino-N-[2-chloro-5-(4-methoxybutoxy)benzyl]-N-cyclopropyl-2-[4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl]propanamide
-
-
3-amino-N-[2-chloro-5-(4-methoxybutyl)benzyl]-N-cyclopropyl-2-[4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl]propanamide
-
-
3-amino-N-[2-chloro-5-(6-methoxyhexyl)benzyl]-N-cyclopropyl-2-[4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl]propanamide
-
-
3-amino-N-[2-chloro-5-[3-(dimethylamino)propyl]benzyl]-N-cyclopropyl-2-[4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl]propanamide
-
-
3-amino-N-[[5-chloro-2-(3-methoxypropyl)-1-oxidopyridin-4-yl]methyl]-N-cyclopropyl-2-[4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl]propanamide
-
-
3-amino-N-[[5-chloro-2-(3-methoxypropyl)pyridin-4-yl]methyl]-N-cyclopropyl-2-[4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl]propanamide
-
-
4-([(2R,4S,5S,7S)-5-amino-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2,8-dimethylnonanoyl]amino)butanoic acid
-
-
4-([(2R,4S,5S,7S)-5-amino-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2,8-dimethylnonanoyl]amino)butyl acetate
-
-
4-([(2R,4S,5S,7S)-5-amino-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2-methylnonanoyl]amino)butanoic acid
-
-
4-([(2R,4S,5S,7S)-5-amino-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2-methylnonanoyl]amino)butyl acetate
-
-
4-amino-N-[2-[2-([2-amino-6-ethyl-5-[4-(3-methoxypropyl)-2,2-dimethyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl]pyrimidin-4-yl]amino)ethyl]phenyl]-3-methoxybenzamide
-
-
4-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-N-cyclopropyl-5,5-difluoro-N-(3-methoxy-2-methylbenzyl)-1,2,5,6-tetrahydropyridine-3-carboxamide
-
-
4-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-N-cyclopropyl-N-(2,3-dichlorobenzyl)-1,2,5,6-tetrahydropyridine-3-carboxamide
-
-
4-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-N-cyclopropyl-N-(2,3-dichlorobenzyl)-5,5-difluoro-1,2,5,6-tetrahydropyridine-3-carboxamide
-
-
4-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-N-cyclopropyl-N-(2,3-dichlorobenzyl)-5,5-dimethyl-1,2,5,6-tetrahydropyridine-3-carboxamide
-
-
4-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-N-cyclopropyl-N-(3-methoxy-2-methylbenzyl)-1,2,5,6-tetrahydropyridine-3-carboxamide
-
-
4-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-N-cyclopropyl-N-(3-methoxy-2-methylbenzyl)-5,5-dimethyl-1,2,5,6-tetrahydropyridine-3-carboxamide
-
-
5-amino-3-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-N-cyclopropyl-N-(2,3-dichlorobenzyl)pentanamide
-
-
5-[4-[(3,5-difluorobenzyl)amino]phenyl]-6-ethylpyrimidine-2,4-diamine
-
-
6-(2,4-diamino-6-ethylpyrimidin-5-yl)-2-(3,5-difluorophenyl)-4-(3-methoxypropyl)-2-methyl-2H-1,4-benzoxazin-3(4H)-one
-
-
6-(2,4-diamino-6-ethylpyrimidin-5-yl)-2-(3,5-difluorophenyl)-4-(3-methoxypropyl)-2H-1,4-benzoxazin-3(4H)-one
-
-
6-ethyl-5-[1-(3-methoxypropyl)-1,2,3,4-tetrahydroquinolin-7-yl]pyrimidine-2,4-diamine
-
-
6-ethyl-5-[1-(3-methoxypropyl)-2-phenyl-1,2,3,4-tetrahydroquinolin-7-yl]pyrimidine-2,4-diamine
-
-
6-ethyl-5-[9-(3-methoxypropyl)-9H-carbazol-2-yl]pyrimidine-2,4-diamine
-
-
7-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-N-cyclopropyl-N-(2,3-dichlorobenzyl)-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxamide
-
-
8-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-N-cyclopropyl-N-(2,3-dichlorobenzyl)-5-azaspiro[2.5]oct-7-ene-7-carboxamide
-
-
8-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-N-cyclopropyl-N-(3-methoxy-2-methylbenzyl)-5-azaspiro[2.5]oct-7-ene-7-carboxamide
-
-
A 62198
-
-
-
A 65317
-
-
-
A 74273
-
-
-
aliskiren
BILA 2157 BS
-
-
-
Bromoisocaproyl peptides
-
-
-
BW 633C
-
-
BW-175
-
-
CGP 29287
-
-
CGP 38560A
-
-
CGP 44099
-
-
CGP 60536
CGP-29,287
-
-
CGP-44099A
-
-
CGP38560A
-
-
chikusetsusaponin IV
-
-
chitooligosaccharide
-
chitooligosaccharides are competitive inhibitors of renin. Chitololigosaccharides from 90% deacetylated chitosan and with molecular weight of 1000-5000 Da exhibit the highest activity with IC50 value of 0.51 mg/ml and Km value of 0.28 mg/ml. Chitooligosaccharides from 90% deacetylated chitosan and with molecular weight below 1000 Da show an IC50 value of 0.59 mg/ml. Main binding sites of chitooligosaccharides are not S3-S1 pockets of renin. Interactions could be formed by the hydrogen bonding and/or the electrostatic interaction between the positively charged amide group at C2 postition and the carboxylates of the catalytic resiudues
-
CI 992
-
-
CI-992
-
-
ciprokiren
-
Ro 44-9375
cod protein hydrolysate
-
non-competitive inhibition, 43% renin-inhibitory activity at 1 mg/ml
-
cod protein hydrolysate fraction CF3
-
non-competitive inhibition, 63% renin-inhibitory activity at 1 mg/ml
-
CP 71362
-
-
CP 81282
-
-
CP-72,647
-
-
CP-80,794
-
-
CP-81,198
-
-
CP-81,282
-
-
cyclothiazomycin
-
-
decanoyl acetal sodium sulfite
-
IC50: 0.273 mM
ditekren
-
U 71038
dodecanoyl acetal sodium sulfite
-
IC50: 0.195 mM
EMD 51921
-
-
EMD 52297
-
-
EMD 56133
-
-
EMD 58265
-
-
enalkiren
ES 1005
-
-
ES 6864
-
-
ES-8891
-
-
ethyl N-[(2R,4S,5S,7S)-5-amino-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2,8-dimethylnonanoyl]-beta-alaninate
-
-
ethyl N-[(2R,4S,5S,7S)-5-amino-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2-methylnonanoyl]-beta-alaninate
-
-
ethyl [(4S)-4-(3-chlorophenyl)-4-[(3R)-1-[[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]carbamoyl]piperidin-3-yl]-4-hydroxybutyl]carbamate
-
-
FK906
-
-
glycyrrhizin
-
-
GR 70982
-
-
H-141
-
-
-
H-142
-
-
H-142-08
-
-
H-189
-
-
H-261
-
-
H-77
-
-
H-77-77
-
-
hexanoyl acetal sodium sulfite
-
-
houttuynin
-
from the volatile oil of Houttuynia cordata
KR1-1314
-
-
-
KRI 1177
-
-
L-Ile-L-Trp
-
70% inhibition at 3.2 mM
L-Leu-L-Trp
-
37% inhibition at 3.2 mM
methyl (2-[(R)-(3-chloro-2-fluorophenyl)[(3R)-1-[[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]carbamoyl]piperidin-3-yl]methoxy]ethyl)carbamate
-
-
methyl (2-[(R)-(3-chloro-5-fluorophenyl)[(3R)-1-[[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]carbamoyl]piperidin-3-yl]methoxy]ethyl)carbamate
-
-
methyl (2-[(R)-(3-chlorophenyl)[(3R)-1-[[(2S)-1-cyclohexyl-3-(ethylamino)propan-2-yl]carbamoyl]piperidin-3-yl]methoxy]ethyl)carbamate
-
-
methyl (2-[(R)-(3-chlorophenyl)[(3R)-1-[[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]carbamoyl]piperidin-3-yl]methoxy]ethyl)carbamate
-
-
methyl (2-[(R)-(5-chloro-2-fluorophenyl)[(3R)-1-[[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]carbamoyl]piperidin-3-yl]methoxy]ethyl)carbamate
-
-
methyl (5-[[(2S,3S,5R)-2-amino-6-(butylamino)-3-hydroxy-5-methyl-6-oxohexyl](propan-2-yl)carbamoyl]-2-methoxybenzyl)carbamate
-
-
methyl 4-([(2R,4S,5S,7S)-5-amino-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2,8-dimethylnonanoyl]amino)butanoate
-
-
methyl [(4S)-4-(3-chlorophenyl)-4-[(3R)-1-[[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]carbamoyl]piperidin-3-yl]-4-hydroxybutyl]carbamate
-
-
methyl [2-(5-[[(2S,3S,5R)-2-amino-6-(butylamino)-3-hydroxy-5-methyl-6-oxohexyl](propan-2-yl)carbamoyl]-2-methoxyphenyl)ethyl]carbamate
-
-
methyl [2-[(R)-[(3R)-1-[[(2S)-1-amino-3-cyclohexylpropan-2-yl]carbamoyl]piperidin-3-yl](3-chlorophenyl)methoxy]ethyl]carbamate
-
-
methyl [2-[(R)-[(3R)-1-[[(2S)-1-amino-3-cyclohexylpropan-2-yl]carbamoyl]piperidin-3-yl](3-fluorophenyl)methoxy]ethyl]carbamate
-
-
methyl [2-[(R)-[(3R)-1-[[(2S)-1-cyclohexyl-3-(ethylamino)propan-2-yl]carbamoyl]piperidin-3-yl](3-fluorophenyl)methoxy]ethyl]carbamate
-
-
methyl [2-[(R)-[(3R)-1-[[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]carbamoyl]piperidin-3-yl](2,3-difluorophenyl)methoxy]ethyl]carbamate
-
-
methyl [2-[(R)-[(3R)-1-[[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]carbamoyl]piperidin-3-yl](2,5-difluorophenyl)methoxy]ethyl]carbamate
-
-
methyl [2-[(R)-[(3R)-1-[[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]carbamoyl]piperidin-3-yl](3,4-difluorophenyl)methoxy]ethyl]carbamate
-
-
methyl [2-[(R)-[(3R)-1-[[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]carbamoyl]piperidin-3-yl](3,5-difluorophenyl)methoxy]ethyl]carbamate
-
-
methyl [2-[(R)-[(3R)-1-[[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]carbamoyl]piperidin-3-yl](3-fluorophenyl)methoxy]ethyl]carbamate
-
-
methyl [2-[(R)-[(3R)-1-[[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]carbamoyl]piperidin-3-yl](3-methylphenyl)methoxy]ethyl]carbamate
-
-
methyl [2-[(R)-[(3R)-1-[[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]carbamoyl]piperidin-3-yl](phenyl)methoxy]ethyl]carbamate
-
-
methyl [5-[(2S,4S,5S,7R)-4-amino-8-(butylamino)-2-ethyl-5-hydroxy-7-methyl-8-oxooctyl]-2-methoxyphenoxy]methanesulfinate
-
-
methyl [5-[(2S,4S,5S,7R)-4-amino-8-(butylamino)-2-ethyl-5-hydroxy-7-methyl-8-oxooctyl]-2-tert-butylphenoxy]acetate
-
-
methyl [5-[(2S,4S,5S,7R)-4-amino-8-(butylamino)-2-ethyl-5-hydroxy-7-methyl-8-oxooctyl]-2-tert-butylphenoxy]methanesulfinate
-
-
methyl [5-[(2S,4S,5S,7R)-4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-2-methoxyphenoxy]acetate
-
-
momordin Ic
-
-
momordin IIc
-
-
monoglucuronyl glycyrrhetic acid
-
-
N-(5-[[acetyl(methyl)amino]methyl]-2-chlorobenzyl)-3-amino-N-cyclopropyl-2-[4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl]propanamide
-
-
N-acetyl-D-glucosamine-2-epimerase
-
-
-
N-cyclopropyl-7-[4-[3-(2,6-dichloro-4-methylphenoxy)propyl]phenyl]-N-(2,3-dimethylbenzyl)-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxamide
-
-
N-cyclopropyl-N-[[1-(3-methoxypropyl)-1H-indol-3-yl]methyl]morpholine-2-carboxamide
-
-
N-[(2R,4S,5S,7S)-5-amino-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2,8-dimethylnonanoyl]-beta-alanine
-
-
N-[(2R,4S,5S,7S)-5-amino-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2-methylnonanoyl]-beta-alanine
-
-
N-[(2S,3S,5R)-2-amino-6-(butylamino)-3-hydroxy-5-methyl-6-oxohexyl]-3-(3-methoxypropoxy)-4-methyl-N-(propan-2-yl)benzamide
-
-
N-[(2S,3S,5R)-2-amino-6-(butylamino)-3-hydroxy-5-methyl-6-oxohexyl]-4-bromo-3-(3-methoxypropoxy)-N-(propan-2-yl)benzamide
-
-
N-[(2S,3S,5R)-2-amino-6-(butylamino)-3-hydroxy-5-methyl-6-oxohexyl]-4-ethyl-3-(3-methoxypropoxy)-N-(propan-2-yl)benzamide
-
-
N-[(2S,3S,5R)-2-amino-6-(butylamino)-3-hydroxy-5-methyl-6-oxohexyl]-4-ethynyl-3-(3-methoxypropoxy)-N-(propan-2-yl)benzamide
-
-
N-[(2S,3S,5R)-2-amino-6-(butylamino)-3-hydroxy-5-methyl-6-oxohexyl]-4-methoxy-3-(3-methoxypropoxy)-N-(propan-2-yl)benzamide
-
-
N-[(2S,3S,5R)-2-amino-6-(butylamino)-3-hydroxy-5-methyl-6-oxohexyl]-4-methoxy-3-(4-methoxybutyl)-N-(propan-2-yl)benzamide
-
-
N-[(2S,3S,5R)-2-amino-6-(butylamino)-3-hydroxy-5-methyl-6-oxohexyl]-4-methoxy-3-[(1E)-4-methoxybut-1-en-1-yl]-N-(propan-2-yl)benzamide
-
-
N-[(2S,3S,5S)-2-amino-5-(butylcarbamoyl)-3-hydroxy-6-methylheptyl]-4-ethyl-3-(3-methoxypropoxy)-N-(propan-2-yl)benzamide
-
-
N-[2-([2-amino-6-ethyl-5-[4-(3-methoxypropyl)-2,2-dimethyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl]pyrimidin-4-yl]amino)ethyl]benzamide
-
-
N-[2-([2-amino-6-ethyl-5-[4-(3-methoxypropyl)-2,2-dimethyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl]pyrimidin-4-yl]amino)ethyl]naphthalene-2-sulfonamide
-
-
N-[2-[6-(2,4-diamino-6-ethylpyrimidin-5-yl)-2,2-dimethyl-3-oxo-2,3-dihydro-4H-1,4-benzoxazin-4-yl]ethyl]acetamide
-
-
N-[2-[7-([[(3R,4R)-4-(4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl)piperidin-3-yl]oxy]methyl)-3,4-dihydroquinolin-1(2H)-yl]ethyl]acetamide
-
-
N-[2-[7-[[(2R)-1-(4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl)piperazin-2-yl]methoxy]-3,4-dihydroquinolin-1(2H)-yl]ethyl]acetamide
-
-
octanoyl acetal sodium sulfite
-
-
PD 132002
-
-
PD 133,450
-
-
PD-129,541
-
-
pepstatin
-
-
pepstatin A
-
SR 42128
R-PEP-27
-
-
remikiren
renin inhibitory peptide
-
-
-
Ro 42-5892
-
-
S-2864
-
-
SC 46944
-
-
SC 56525
-
-
soyasaponin I
soyasaponin II
-
-
-
SQ 32970
-
-
SQ 33800
-
-
SR 43845
-
-
terlakiren
-
CP 80794
tert-butyl [(3S,5S,6S,8S)-8-(butylcarbamoyl)-6-hydroxy-3-(4-methoxybenzyl)-2,9-dimethyldecan-5-yl]carbamate
-
potent low nanomolar inhibitor of renin
tetradecanoyl acetal sodium sulfite
-
complex formation with the enzyme, mixed inhibition type, IC50: 0.044 mM
tetrahydro-2H-pyran-4-yl cyclopropyl[[(3S,4S)-4-[(2R)-2-[4-methoxy-3-(3-methoxypropoxy)benzyl]-3-methylbutyl]pyrrolidin-3-yl]methyl]carbamate
-
-
transition state analogues
-
U-62168E
-
-
U-71909E
-
-
U-72407E
-
-
U-72408E
-
-
U-72409E
-
-
U-73777E
-
-
U-76780E
-
-
U-77451E
-
-
U-77455E
-
-
U-77646E
-
-
U-77647E
-
-
U-80215E
-
-
U-80631E
-
-
YM-21095
-
-
YM-26365
-
-
YY
-
dipeptide derived from royal jelly proteins. YY inhibits the renin activity only at acidic pH values below 8.0
zankiren
additional information
-
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.00076
angiotensinogen
at pH 7.4 and 37°C
0.01937
Arg-Glu(EDANS)-Ile-His-Pro-Phe-His-Leu-Val-Ile-His-Thr-Lys(DABCYL)-Arg
at pH 8.0 and 37°C
0.0036
4-(4-dimethylaminophenylazo)benzoic acid-IHPFHLVIHT-5-[(e-amino-ethyl)amino]naphthalene-1-sulfonic acid
-
-
0.00029 - 0.00204
angiotensinogen
0.0064
Arg-Glu(5-[(2-aminoethyl)amino]-naphthalene-1-sulfonic acid)-Ile-His-Pro-Phe-His-Leu-Val-Ile-His-Thr-Lys(4-(4-dimethylaminophenylazo)-benzoic acid)-Arg
-
pH 8.0, 37°C
0.000072
recombinant ovine angiotensinogen from CHO cells
-
at pH 7.2 and 37°C
-
0.000071
recombinant ovine angiotensinogen from Escherichia coli
-
at pH 7.2 and 37°C
-
additional information
aliskiren
-
estimated Km1 value is 0.516 ng/ml, Km2 value is 135 ng/ml
TURNOVER NUMBER [1/s]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.2
angiotensinogen
at pH 7.4 and 37°C
1.35
angiotensinogen
-
pH 6.0, 37°C, maleate buffer
0.46
recombinant ovine angiotensinogen from CHO cells
-
at pH 7.2 and 37°C
-
0.59
recombinant ovine angiotensinogen from Escherichia coli
-
at pH 7.2 and 37°C
-
kcat/KM VALUE [1/mMs-1]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
250
angiotensinogen
at pH 7.4 and 37°C
6400
recombinant ovine angiotensinogen from CHO cells
-
at pH 7.2 and 37°C
-
8300
recombinant ovine angiotensinogen from Escherichia coli
-
at pH 7.2 and 37°C
-
Ki VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.013
Pro-Arg-Tyr
at pH 8.0 and 37°C
0.14
Trp-Gly
at pH 8.0 and 37°C
0.000021
(3R)-3-[(1S)-1-(3-chlorophenyl)-1,5-dihydroxypentyl]-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]piperidine-1-carboxamide
-
50 mM BES buffer, 150 mM NaCl, 0.25 mg/ml bovine serum albumin, pH 7.0, at 25°C
0.0000015
(3R)-3-[(1S)-1-(3-chlorophenyl)-1-hydroxy-4-(propanoylamino)butyl]-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]piperidine-1-carboxamide
-
50 mM BES buffer, 150 mM NaCl, 0.25 mg/ml bovine serum albumin, pH 7.0, at 25°C
0.000046
(3R)-3-[(1S)-1-(3-chlorophenyl)-1-hydroxy-4-(sulfamoylamino)butyl]-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]piperidine-1-carboxamide
-
50 mM BES buffer, 150 mM NaCl, 0.25 mg/ml bovine serum albumin, pH 7.0, at 25°C
0.000046
(3R)-3-[(1S)-1-(3-chlorophenyl)-1-hydroxy-4-[(methylcarbamoyl)amino]butyl]-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]piperidine-1-carboxamide
-
50 mM BES buffer, 150 mM NaCl, 0.25 mg/ml bovine serum albumin, pH 7.0, at 25°C
0.000177
(3R)-3-[(1S)-1-(3-chlorophenyl)-1-hydroxy-4-[(methylsulfonyl)amino]butyl]-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]piperidine-1-carboxamide
-
50 mM BES buffer, 150 mM NaCl, 0.25 mg/ml bovine serum albumin, pH 7.0, at 25°C
0.00000047
(3R)-3-[(1S)-1-(3-chlorophenyl)-1-hydroxy-5-methoxypentyl]-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]piperidine-1-carboxamide
-
50 mM BES buffer, 150 mM NaCl, 0.25 mg/ml bovine serum albumin, pH 7.0, at 25°C
0.000017
(3R)-3-[(1S)-1-(3-chlorophenyl)-4-[(cyclopropylcarbonyl)amino]-1-hydroxybutyl]-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]piperidine-1-carboxamide
-
50 mM BES buffer, 150 mM NaCl, 0.25 mg/ml bovine serum albumin, pH 7.0, at 25°C
0.00226
(3R)-3-[(1S)-1-(3-chlorophenyl)-4-[(dimethylcarbamoyl)amino]-1-hydroxybutyl]-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]piperidine-1-carboxamide
-
50 mM BES buffer, 150 mM NaCl, 0.25 mg/ml bovine serum albumin, pH 7.0, at 25°C
0.0000013
(3R)-3-[(1S)-4-(acetylamino)-1-(3-chlorophenyl)-1-hydroxybutyl]-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]piperidine-1-carboxamide
-
50 mM BES buffer, 150 mM NaCl, 0.25 mg/ml bovine serum albumin, pH 7.0, at 25°C
0.000057
(3R)-3-[(1S)-4-(butanoylamino)-1-(3-chlorophenyl)-1-hydroxybutyl]-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]piperidine-1-carboxamide
-
50 mM BES buffer, 150 mM NaCl, 0.25 mg/ml bovine serum albumin, pH 7.0, at 25°C
0.000031
(3R)-3-[(1S)-4-(carbamoylamino)-1-(3-chlorophenyl)-1-hydroxybutyl]-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]piperidine-1-carboxamide
-
50 mM BES buffer, 150 mM NaCl, 0.25 mg/ml bovine serum albumin, pH 7.0, at 25°C
0.00004
(3R)-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]-3-[(R)-(3-ethoxypropoxy)(phenyl)methyl]piperidine-1-carboxamide
-
50 mM BES buffer, 150 mM NaCl, 0.25 mg/ml bovine serum albumin, pH 7.0, at 25°C
3.294
cod protein hydrolysate
-
at pH 8.0 and 37°C
-
2.152
cod protein hydrolysate fraction CF3
-
at pH 8.0 and 37°C
-
0.000014
ethyl [(4S)-4-(3-chlorophenyl)-4-[(3R)-1-[[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]carbamoyl]piperidin-3-yl]-4-hydroxybutyl]carbamate
-
50 mM BES buffer, 150 mM NaCl, 0.25 mg/ml bovine serum albumin, pH 7.0, at 25°C
0.00000061
methyl (2-[(R)-(3-chloro-2-fluorophenyl)[(3R)-1-[[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]carbamoyl]piperidin-3-yl]methoxy]ethyl)carbamate
-
50 mM BES buffer, 150 mM NaCl, 0.25 mg/ml bovine serum albumin, pH 7.0, at 25°C
0.00000053
methyl (2-[(R)-(3-chloro-5-fluorophenyl)[(3R)-1-[[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]carbamoyl]piperidin-3-yl]methoxy]ethyl)carbamate
-
50 mM BES buffer, 150 mM NaCl, 0.25 mg/ml bovine serum albumin, pH 7.0, at 25°C
0.00000087
methyl (2-[(R)-(3-chlorophenyl)[(3R)-1-[[(2S)-1-cyclohexyl-3-(ethylamino)propan-2-yl]carbamoyl]piperidin-3-yl]methoxy]ethyl)carbamate
-
50 mM BES buffer, 150 mM NaCl, 0.25 mg/ml bovine serum albumin, pH 7.0, at 25°C
0.00000048
methyl (2-[(R)-(3-chlorophenyl)[(3R)-1-[[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]carbamoyl]piperidin-3-yl]methoxy]ethyl)carbamate
-
50 mM BES buffer, 150 mM NaCl, 0.25 mg/ml bovine serum albumin, pH 7.0, at 25°C
0.00000062
methyl (2-[(R)-(5-chloro-2-fluorophenyl)[(3R)-1-[[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]carbamoyl]piperidin-3-yl]methoxy]ethyl)carbamate
-
50 mM BES buffer, 150 mM NaCl, 0.25 mg/ml bovine serum albumin, pH 7.0, at 25°C
0.00000018
methyl [(4S)-4-(3-chlorophenyl)-4-[(3R)-1-[[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]carbamoyl]piperidin-3-yl]-4-hydroxybutyl]carbamate
-
50 mM BES buffer, 150 mM NaCl, 0.25 mg/ml bovine serum albumin, pH 7.0, at 25°C
0.00000048
methyl [2-[(R)-[(3R)-1-[[(2S)-1-amino-3-cyclohexylpropan-2-yl]carbamoyl]piperidin-3-yl](3-chlorophenyl)methoxy]ethyl]carbamate
-
50 mM BES buffer, 150 mM NaCl, 0.25 mg/ml bovine serum albumin, pH 7.0, at 25°C
0.00000058
methyl [2-[(R)-[(3R)-1-[[(2S)-1-amino-3-cyclohexylpropan-2-yl]carbamoyl]piperidin-3-yl](3-fluorophenyl)methoxy]ethyl]carbamate
-
50 mM BES buffer, 150 mM NaCl, 0.25 mg/ml bovine serum albumin, pH 7.0, at 25°C
0.0000021
methyl [2-[(R)-[(3R)-1-[[(2S)-1-cyclohexyl-3-(ethylamino)propan-2-yl]carbamoyl]piperidin-3-yl](3-fluorophenyl)methoxy]ethyl]carbamate
-
50 mM BES buffer, 150 mM NaCl, 0.25 mg/ml bovine serum albumin, pH 7.0, at 25°C
0.0000017
methyl [2-[(R)-[(3R)-1-[[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]carbamoyl]piperidin-3-yl](2,3-difluorophenyl)methoxy]ethyl]carbamate
-
50 mM BES buffer, 150 mM NaCl, 0.25 mg/ml bovine serum albumin, pH 7.0, at 25°C
0.00000062
methyl [2-[(R)-[(3R)-1-[[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]carbamoyl]piperidin-3-yl](2,5-difluorophenyl)methoxy]ethyl]carbamate
-
50 mM BES buffer, 150 mM NaCl, 0.25 mg/ml bovine serum albumin, pH 7.0, at 25°C
0.0000025
methyl [2-[(R)-[(3R)-1-[[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]carbamoyl]piperidin-3-yl](3,4-difluorophenyl)methoxy]ethyl]carbamate
-
50 mM BES buffer, 150 mM NaCl, 0.25 mg/ml bovine serum albumin, pH 7.0, at 25°C
0.00000023
methyl [2-[(R)-[(3R)-1-[[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]carbamoyl]piperidin-3-yl](3,5-difluorophenyl)methoxy]ethyl]carbamate
-
50 mM BES buffer, 150 mM NaCl, 0.25 mg/ml bovine serum albumin, pH 7.0, at 25°C
0.00000059
methyl [2-[(R)-[(3R)-1-[[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]carbamoyl]piperidin-3-yl](3-fluorophenyl)methoxy]ethyl]carbamate
-
50 mM BES buffer, 150 mM NaCl, 0.25 mg/ml bovine serum albumin, pH 7.0, at 25°C
0.00000047
methyl [2-[(R)-[(3R)-1-[[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]carbamoyl]piperidin-3-yl](3-methylphenyl)methoxy]ethyl]carbamate
-
50 mM BES buffer, 150 mM NaCl, 0.25 mg/ml bovine serum albumin, pH 7.0, at 25°C
0.00000117
methyl [2-[(R)-[(3R)-1-[[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]carbamoyl]piperidin-3-yl](phenyl)methoxy]ethyl]carbamate
-
50 mM BES buffer, 150 mM NaCl, 0.25 mg/ml bovine serum albumin, pH 7.0, at 25°C
0.0375
soyasaponin I
-
pH 6.5, 37°C
0.045
tetradecanoyl acetal sodium sulfite
-
pH 8.0, 37°C
additional information
chitooligosaccharide
-
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.000007
(3R)-3-[(1S)-1-(2-chlorophenyl)-1-hydroxy-5-methoxypentyl]-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]piperidine-1-carboxamide
Homo sapiens
in 50 mM BES buffer, 150 mM NaCl, 0.25 mg/ml bovine serum albumin, pH 7.0, at 25°C
0.00000013
(3R)-3-[(1S)-1-(3-bromophenyl)-1-hydroxy-5-methoxypentyl]-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]piperidine-1-carboxamide
Homo sapiens
in 50 mM BES buffer, 150 mM NaCl, 0.25 mg/ml bovine serum albumin, pH 7.0, at 25°C
0.0000001
(3R)-3-[(1S)-1-(3-chloro-2-fluorophenyl)-1-hydroxy-5-methoxypentyl]-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]piperidine-1-carboxamide
Homo sapiens
in 50 mM BES buffer, 150 mM NaCl, 0.25 mg/ml bovine serum albumin, pH 7.0, at 25°C
0.0000009
(3R)-3-[(1S)-1-(3-chloro-5-fluorophenyl)-1-hydroxy-5-methoxypentyl]-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]piperidine-1-carboxamide
Homo sapiens
in 50 mM BES buffer, 150 mM NaCl, 0.25 mg/ml bovine serum albumin, pH 7.0, at 25°C
0.000021
(3R)-3-[(1S)-1-(3-chlorophenyl)-1,5-dihydroxypentyl]-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]piperidine-1-carboxamide
Homo sapiens
in 50 mM BES buffer, 150 mM NaCl, 0.25 mg/ml bovine serum albumin, pH 7.0, at 25°C
0.00000047
(3R)-3-[(1S)-1-(3-chlorophenyl)-1-hydroxy-5-methoxypentyl]-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]piperidine-1-carboxamide
Homo sapiens
in 50 mM BES buffer, 150 mM NaCl, 0.25 mg/ml bovine serum albumin, pH 7.0, at 25°C
0.000046
(3R)-3-[(1S)-1-(3-chlorophenyl)-1-hydroxy-5-methoxypentyl]-N-[(2S)-1-cyclohexyl-3-[(2,2,2-trifluoroethyl)amino]propan-2-yl]piperidine-1-carboxamide
Homo sapiens
in 50 mM BES buffer, 150 mM NaCl, 0.25 mg/ml bovine serum albumin, pH 7.0, at 25°C
0.000037
(3R)-3-[(1S)-1-(3-cyanophenyl)-1-hydroxy-5-methoxypentyl]-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]piperidine-1-carboxamide
Homo sapiens
in 50 mM BES buffer, 150 mM NaCl, 0.25 mg/ml bovine serum albumin, pH 7.0, at 25°C
0.000039
(3R)-3-[(R)-(3-chloro-2-fluorophenyl)(3-methoxypropoxy)methyl]-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]piperidine-1-carboxamide
Homo sapiens
in 50 mM BES buffer, 150 mM NaCl, 0.25 mg/ml bovine serum albumin, pH 7.0, at 25°C
0.000004
(3R)-3-[(R)-(3-chlorophenyl)(3-ethoxypropoxy)methyl]-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]piperidine-1-carboxamide
Homo sapiens
in 50 mM BES buffer, 150 mM NaCl, 0.25 mg/ml bovine serum albumin, pH 7.0, at 25°C
0.000764
(3R)-3-[(R)-(3-chlorophenyl)(3-hydroxypropoxy)methyl]-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]piperidine-1-carboxamide
Homo sapiens
in 50 mM BES buffer, 150 mM NaCl, 0.25 mg/ml bovine serum albumin, pH 7.0, at 25°C
0.000021
(3R)-N-[(2S)-1-amino-3-cyclohexylpropan-2-yl]-3-[(1S)-1-hydroxy-5-methoxy-1-phenylpentyl]piperidine-1-carboxamide
Homo sapiens
in 50 mM BES buffer, 150 mM NaCl, 0.25 mg/ml bovine serum albumin, pH 7.0, at 25°C
0.000038
(3R)-N-[(2S)-1-amino-3-cyclohexylpropan-2-yl]-3-[(1S)-5-ethoxy-1-hydroxy-1-phenylpentyl]piperidine-1-carboxamide
Homo sapiens
in 50 mM BES buffer, 150 mM NaCl, 0.25 mg/ml bovine serum albumin, pH 7.0, at 25°C
0.0000055
(3R)-N-[(2S)-1-amino-3-cyclohexylpropan-2-yl]-3-[(R)-(3-chlorophenyl)(3-ethoxypropoxy)methyl]piperidine-1-carboxamide
Homo sapiens
in 50 mM BES buffer, 150 mM NaCl, 0.25 mg/ml bovine serum albumin, pH 7.0, at 25°C
0.000055
(3R)-N-[(2S)-1-amino-3-cyclohexylpropan-2-yl]-3-[(R)-(3-ethoxypropoxy)(phenyl)methyl]piperidine-1-carboxamide
Homo sapiens
in 50 mM BES buffer, 150 mM NaCl, 0.25 mg/ml bovine serum albumin, pH 7.0, at 25°C
0.000308
(3R)-N-[(2S)-1-amino-3-cyclohexylpropan-2-yl]-3-[(R)-(3-methoxypropoxy)(phenyl)methyl]piperidine-1-carboxamide
Homo sapiens
in 50 mM BES buffer, 150 mM NaCl, 0.25 mg/ml bovine serum albumin, pH 7.0, at 25°C
0.00000014
(3R)-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]-3-[(1S)-1-(2,3-difluorophenyl)-1-hydroxy-5-methoxypentyl]piperidine-1-carboxamide
Homo sapiens
in 50 mM BES buffer, 150 mM NaCl, 0.25 mg/ml bovine serum albumin, pH 7.0, at 25°C
0.0000035
(3R)-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]-3-[(1S)-1-(2-fluoro-5-methylphenyl)-1-hydroxy-5-methoxypentyl]piperidine-1-carboxamide
Homo sapiens
in 50 mM BES buffer, 150 mM NaCl, 0.25 mg/ml bovine serum albumin, pH 7.0, at 25°C
0.000004
(3R)-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]-3-[(1S)-1-(2-fluorophenyl)-1-hydroxy-5-methoxypentyl]piperidine-1-carboxamide
Homo sapiens
in 50 mM BES buffer, 150 mM NaCl, 0.25 mg/ml bovine serum albumin, pH 7.0, at 25°C
0.000009
(3R)-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]-3-[(1S)-1-(3-ethylphenyl)-1-hydroxy-5-methoxypentyl]piperidine-1-carboxamide
Homo sapiens
in 50 mM BES buffer, 150 mM NaCl, 0.25 mg/ml bovine serum albumin, pH 7.0, at 25°C
0.000003
(3R)-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]-3-[(1S)-1-(3-fluorophenyl)-1-hydroxy-5-methoxypentyl]piperidine-1-carboxamide
Homo sapiens
in 50 mM BES buffer, 150 mM NaCl, 0.25 mg/ml bovine serum albumin, pH 7.0, at 25°C
0.000013
(3R)-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]-3-[(1S)-1-hydroxy-5-methoxy-1-(3-methoxyphenyl)pentyl]piperidine-1-carboxamide
Homo sapiens
in 50 mM BES buffer, 150 mM NaCl, 0.25 mg/ml bovine serum albumin, pH 7.0, at 25°C
0.0000025
(3R)-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]-3-[(1S)-1-hydroxy-5-methoxy-1-(3-methylphenyl)pentyl]piperidine-1-carboxamide
Homo sapiens
in 50 mM BES buffer, 150 mM NaCl, 0.25 mg/ml bovine serum albumin, pH 7.0, at 25°C
0.000007
(3R)-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]-3-[(1S)-1-hydroxy-5-methoxy-1-phenylpentyl]piperidine-1-carboxamide
Homo sapiens
in 50 mM BES buffer, 150 mM NaCl, 0.25 mg/ml bovine serum albumin, pH 7.0, at 25°C
0.000069
(3R)-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]-3-[(1S)-1-hydroxy-5-methoxy-1-[3-(trifluoromethoxy)phenyl]pentyl]piperidine-1-carboxamide
Homo sapiens
in 50 mM BES buffer, 150 mM NaCl, 0.25 mg/ml bovine serum albumin, pH 7.0, at 25°C
0.000007
(3R)-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]-3-[(1S)-1-hydroxy-5-methoxy-1-[3-(trifluoromethyl)phenyl]pentyl]piperidine-1-carboxamide
Homo sapiens
in 50 mM BES buffer, 150 mM NaCl, 0.25 mg/ml bovine serum albumin, pH 7.0, at 25°C
0.000016
(3R)-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]-3-[(1S)-5-ethoxy-1-hydroxy-1-phenylpentyl]piperidine-1-carboxamide
Homo sapiens
in 50 mM BES buffer, 150 mM NaCl, 0.25 mg/ml bovine serum albumin, pH 7.0, at 25°C
0.000125
(3R)-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]-3-[(R)-(2,3-dichlorophenyl)(3-ethoxypropoxy)methyl]piperidine-1-carboxamide
Homo sapiens
in 50 mM BES buffer, 150 mM NaCl, 0.25 mg/ml bovine serum albumin, pH 7.0, at 25°C
0.000609
(3R)-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]-3-[(R)-(2,3-dichlorophenyl)(3-methoxypropoxy)methyl]piperidine-1-carboxamide
Homo sapiens
in 50 mM BES buffer, 150 mM NaCl, 0.25 mg/ml bovine serum albumin, pH 7.0, at 25°C
0.000011
(3R)-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]-3-[(R)-(3-ethoxypropoxy)(3-fluorophenyl)methyl]piperidine-1-carboxamide
Homo sapiens
in 50 mM BES buffer, 150 mM NaCl, 0.25 mg/ml bovine serum albumin, pH 7.0, at 25°C
0.00004
(3R)-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]-3-[(R)-(3-ethoxypropoxy)(phenyl)methyl]piperidine-1-carboxamide
Homo sapiens
in 50 mM BES buffer, 150 mM NaCl, 0.25 mg/ml bovine serum albumin, pH 7.0, at 25°C
0.000058
(3R)-N-[(2S)-1-cyclohexyl-3-(methylamino)propan-2-yl]-3-[(R)-(3-fluorophenyl)(3-methoxypropoxy)methyl]piperidine-1-carboxamide
Homo sapiens
in 50 mM BES buffer, 150 mM NaCl, 0.25 mg/ml bovine serum albumin, pH 7.0, at 25°C
0.000006
(3R)-N-[(2S)-1-[(chloromethyl)amino]-3-cyclohexylpropan-2-yl]-3-[(1S)-1-(3-chlorophenyl)-1-hydroxy-5-methoxypentyl]piperidine-1-carboxamide
Homo sapiens
in 50 mM BES buffer, 150 mM NaCl, 0.25 mg/ml bovine serum albumin, pH 7.0, at 25°C
0.00000055 - 0.00056
3-(5-amino-5-oxopentanoyl)-7-[4-[3-(2-bromo-5-fluorophenoxy)propyl]phenyl]-N-(2-chlorobenzyl)-N-cyclopropyl-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxamide
0.0000004 - 0.00036
7-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-N-cyclopropyl-N-(2,3-dichlorobenzyl)-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxamide
0.0000005
aliskiren
Homo sapiens
in 50 mM BES, 150 mM NaCl, 0.25 mg/ml bovine serum albumin, pH 7.0, temperature not specified in the publication
0.0000002 - 0.00019
N-cyclopropyl-7-[4-[3-(2,6-dichloro-4-methylphenoxy)propyl]phenyl]-N-(2,3-dimethylbenzyl)-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxamide
0.09533
Pro-Arg-Tyr
Homo sapiens
at pH 8.0 and 37°C
0.11234
Trp-Gly
Homo sapiens
at pH 8.0 and 37°C
0.0000004
(1S)-7-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-N-cyclopropyl-N-(2,3-dichlorobenzyl)-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.00000068
(1S)-7-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-N-cyclopropyl-N-(2,3-dichlorobenzyl)-3-oxa-9-azabicyclo[3.3.1]non-6-ene-6-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0000064
(1S)-7-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-N-cyclopropyl-N-(2,3-dichlorobenzyl)-3-thia-9-azabicyclo[3.3.1]non-6-ene-6-carboxamide 3,3-dioxide
Homo sapiens
-
pH and temperature not specified in the publication
0.00000137
(1S)-7-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-N-cyclopropyl-N-(3-methoxy-2-methylbenzyl)-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.00000049
(1S)-7-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-N-cyclopropyl-N-(3-methoxy-2-methylbenzyl)-3-oxa-9-azabicyclo[3.3.1]non-6-ene-6-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000064
(1S)-7-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-N-cyclopropyl-N-(3-methoxy-2-methylbenzyl)-3-thia-9-azabicyclo[3.3.1]non-6-ene-6-carboxamide 3-oxide
Homo sapiens
-
pH and temperature not specified in the publication
0.00000002
(2R)-3-amino-N-cyclopropyl-2-[4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl]-N-[3-(2-methoxyethoxy)-5-(3-methoxypropyl)benzyl]propanamide
Homo sapiens
-
at pH 7.4 and 37°C
0.000132
(2R)-6-(2,4-diamino-6-ethylpyrimidin-5-yl)-4-(3-methoxypropyl)-2-methyl-2H-1,4-benzoxazin-3(4H)-one
Homo sapiens
-
-
0.1
(2R,4S,5S)-5-amino-N-butyl-4-hydroxy-6-[[(4-methoxyphenyl)sulfonyl](propan-2-yl)amino]-2-methylhexanamide
Homo sapiens
-
IC50 above 0.1 mM, at pH 7.4, temperature not specified in the publication
0.000013
(2R,4S,5S)-5-amino-N-butyl-4-hydroxy-6-[[4-methoxy-3-(3-methoxypropoxy)benzyl](propan-2-yl)amino]-2-methylhexanamide
Homo sapiens
-
at pH 7.4, temperature not specified in the publication
0.0003
(2R,4S,5S)-5-amino-N-butyl-4-hydroxy-6-[[[4-methoxy-3-(3-methoxypropoxy)phenyl]sulfonyl](propan-2-yl)amino]-2-methylhexanamide
Homo sapiens
-
at pH 7.4, temperature not specified in the publication
0.000002
(2R,4S,5S,7S)-5-amino-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2,8-dimethyl-N-(2-methyl-2-morpholin-4-ylpropyl)nonanamide
Homo sapiens
-
pH 7.2, 37°C, purified enzyme
0.000002
(2R,4S,5S,7S)-5-amino-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2,8-dimethyl-N-(2-morpholin-4-ylethyl)nonanamide
Homo sapiens
-
pH 7.2, 37°C, purified enzyme
0.000022
(2R,4S,5S,7S)-5-amino-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2,8-dimethyl-N-(2-piperidin-1-ylethyl)nonanamide
Homo sapiens
-
pH 7.2, 37°C, purified enzyme
0.000008
(2R,4S,5S,7S)-5-amino-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2,8-dimethyl-N-(2-pyridin-2-ylethyl)nonanamide
Homo sapiens
-
pH 7.2, 37°C, purified enzyme
0.000002
(2R,4S,5S,7S)-5-amino-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2,8-dimethyl-N-(2-thiomorpholin-4-ylethyl)nonanamide
Homo sapiens
-
pH 7.2, 37°C, purified enzyme
0.000011
(2R,4S,5S,7S)-5-amino-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2,8-dimethyl-N-(3-morpholin-4-ylpropyl)nonanamide
Homo sapiens
-
pH 7.2, 37°C, purified enzyme
0.000002
(2R,4S,5S,7S)-5-amino-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2,8-dimethyl-N-(4-morpholin-4-yl-4-oxobutyl)nonanamide
Homo sapiens
-
pH 7.2, 37°C, purified enzyme
0.000003
(2R,4S,5S,7S)-5-amino-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2,8-dimethyl-N-[3-(1H-tetrazol-5-yl)propyl]nonanamide
Homo sapiens
-
pH 7.2, 37°C, purified enzyme
0.000002
(2R,4S,5S,7S)-5-amino-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2,8-dimethyl-N-[3-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]nonanamide
Homo sapiens
-
pH 7.2, 37°C, purified enzyme
0.000003
(2R,4S,5S,7S)-5-amino-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2,8-dimethyl-N-[4-(methylamino)-4-oxobutyl]nonanamide
Homo sapiens
-
pH 7.2, 37°C, purified enzyme
0.000022
(2R,4S,5S,7S)-5-amino-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2-methyl-N-[2-(piperidin-1-yl)ethyl]nonanamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000008
(2R,4S,5S,7S)-5-amino-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2-methyl-N-[2-(pyridin-2-yl)ethyl]nonanamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000003
(2R,4S,5S,7S)-5-amino-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2-methyl-N-[3-(1H-tetrazol-5-yl)propyl]nonanamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000011
(2R,4S,5S,7S)-5-amino-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2-methyl-N-[3-(morpholin-4-yl)propyl]nonanamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0000004
(2R,4S,5S,7S)-5-amino-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-N-(3-methoxypropyl)-2,8-dimethylnonanamide
Homo sapiens
-
pH 7.2, 37°C, purified enzyme
0.000005
(2R,4S,5S,7S)-5-amino-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-N-[2-(4-methoxypiperidin-1-yl)ethyl]-2,8-dimethylnonanamide
Homo sapiens
-
pH 7.2, 37°C, purified enzyme
0.000002
(2R,4S,5S,7S)-5-amino-4-hydroxy-N-(3-hydroxypropyl)-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2,8-dimethylnonanamide
Homo sapiens
-
pH 7.2, 37°C, purified enzyme
0.0000008
(2R,4S,5S,7S)-5-amino-4-hydroxy-N-(4-hydroxybutyl)-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2,8-dimethylnonanamide
Homo sapiens
-
pH 7.2, 37°C, purified enzyme
0.00001
(2R,4S,5S,7S)-5-amino-4-hydroxy-N-[(4-hydroxypiperidin-1-yl)methyl]-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2-methylnonanamide
Homo sapiens
-
pH and temperature not specified in the publication
0.00001
(2R,4S,5S,7S)-5-amino-4-hydroxy-N-[2-(4-hydroxypiperidin-1-yl)ethyl]-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2,8-dimethylnonanamide
Homo sapiens
-
pH 7.2, 37°C, purified enzyme
0.000004
(2R,4S,5S,7S)-5-amino-4-hydroxy-N-[3-(1H-imidazol-4-yl)propyl]-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2,8-dimethylnonanamide
Homo sapiens
-
pH 7.2, 37°C, purified enzyme
0.000002
(2R,4S,5S,7S)-5-amino-4-hydroxy-N-[4-[(2-methoxyethyl)amino]-4-oxobutyl]-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2,8-dimethylnonanamide
Homo sapiens
-
pH 7.2, 37°C, purified enzyme
0.000092
(2R,4S,5S,7S)-5-amino-7-[3-(2-amino-2-oxoethoxy)-4-methoxybenzyl]-N-butyl-4-hydroxy-2,8-dimethylnonanamide
Homo sapiens
-
pH 7.2, 37°C, purified enzyme
0.000092
(2R,4S,5S,7S)-5-amino-7-[3-(2-amino-2-oxoethoxy)-4-methoxybenzyl]-N-butyl-4-hydroxy-2-methylnonanamide
Homo sapiens
-
pH and temperature not specified in the publication
0.00002
(2R,4S,5S,7S)-5-amino-7-[3-(2-amino-2-oxoethoxy)-4-tert-butylbenzyl]-N-butyl-4-hydroxy-2-methylnonanamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0000006
(2R,4S,5S,7S)-5-amino-7-[3-(benzyloxy)-4-methoxybenzyl]-N-butyl-4-hydroxy-2,8-dimethylnonanamide
Homo sapiens
-
pH 7.2, 37°C, purified enzyme
0.000016
(2R,4S,5S,7S)-5-amino-N-(2-aminoethyl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2-methylnonanamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000007
(2R,4S,5S,7S)-5-amino-N-(3-amino-3-oxopropyl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2,8-dimethylnonanamide
Homo sapiens
-
pH 7.2, 37°C, purified enzyme
0.000007
(2R,4S,5S,7S)-5-amino-N-(3-amino-3-oxopropyl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2-methylnonanamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000016
(2R,4S,5S,7S)-5-amino-N-(3-aminopropyl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2,8-dimethylnonanamide
Homo sapiens
-
pH 7.2, 37°C, purified enzyme
0.000001
(2R,4S,5S,7S)-5-amino-N-(3-cyanopropyl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2,8-dimethylnonanamide
Homo sapiens
-
pH 7.2, 37°C, purified enzyme
0.000001
(2R,4S,5S,7S)-5-amino-N-(4-amino-4-oxobutyl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2,8-dimethylnonanamide
Homo sapiens
-
pH 7.2, 37°C, purified enzyme
0.000001
(2R,4S,5S,7S)-5-amino-N-(4-amino-4-oxobutyl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2-methylnonanamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000002
(2R,4S,5S,7S)-5-amino-N-(5-amino-5-oxopentyl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2,8-dimethylnonanamide
Homo sapiens
-
pH 7.2, 37°C, purified enzyme
0.000002
(2R,4S,5S,7S)-5-amino-N-(5-amino-5-oxopentyl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2-methylnonanamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000006
(2R,4S,5S,7S)-5-amino-N-butyl-4-hydroxy-7-[3-(3-hydroxypropoxy)-4-methoxybenzyl]-2,8-dimethylnonanamide
Homo sapiens
-
pH 7.2, 37°C, purified enzyme
0.000006
(2R,4S,5S,7S)-5-amino-N-butyl-4-hydroxy-7-[3-(3-hydroxypropoxy)-4-methoxybenzyl]-2-methylnonanamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000011
(2R,4S,5S,7S)-5-amino-N-butyl-4-hydroxy-7-[4-methoxy-3-(2-methoxyethoxy)benzyl]-2,8-dimethylnonanamide
Homo sapiens
-
pH 7.2, 37°C, purified enzyme
0.000001
(2R,4S,5S,7S)-5-amino-N-butyl-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2,8-dimethylnonanamide
0.000001 - 0.000002
(2R,4S,5S,7S)-5-amino-N-butyl-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2-methylnonanamide
0.000002
(2R,4S,5S,7S)-5-amino-N-butyl-4-hydroxy-7-[4-methoxy-3-(4-methoxybutoxy)benzyl]-2,8-dimethylnonanamide
Homo sapiens
-
pH 7.2, 37°C, purified enzyme
0.000004
(2R,4S,5S,7S)-5-amino-N-butyl-4-hydroxy-7-[4-methoxy-3-(pentyloxy)benzyl]-2,8-dimethylnonanamide
Homo sapiens
-
pH 7.2, 37°C, purified enzyme
0.000004
(2R,4S,5S,7S)-5-amino-N-butyl-4-hydroxy-7-[4-methoxy-3-(pentyloxy)benzyl]-2-methylnonanamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000005
(2R,4S,5S,7S)-5-amino-N-butyl-4-hydroxy-7-[4-methoxy-3-(pyridin-4-ylmethoxy)benzyl]-2,8-dimethylnonanamide
Homo sapiens
-
pH 7.2, 37°C, purified enzyme
0.00005
(2R,4S,5S,7S)-5-amino-N-butyl-4-hydroxy-7-[4-methoxy-3-[(methylsulfonyl)methoxy]benzyl]-2,8-dimethylnonanamide
Homo sapiens
-
pH 7.2, 37°C, purified enzyme
0.000019
(2R,4S,5S,7S)-5-amino-N-butyl-4-hydroxy-7-[4-methoxy-3-[2-(2-methoxyethoxy)ethoxy]benzyl]-2,8-dimethylnonanamide
Homo sapiens
-
pH 7.2, 37°C, purified enzyme
0.000019
(2R,4S,5S,7S)-5-amino-N-butyl-4-hydroxy-7-[4-methoxy-3-[2-(2-methoxyethoxy)ethoxy]benzyl]-2-methylnonanamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000042
(2R,4S,5S,7S)-5-amino-N-butyl-4-hydroxy-7-[4-methoxy-3-[2-(methylamino)-2-oxoethoxy]benzyl]-2,8-dimethylnonanamide
Homo sapiens
-
pH 7.2, 37°C, purified enzyme
0.000042
(2R,4S,5S,7S)-5-amino-N-butyl-4-hydroxy-7-[4-methoxy-3-[2-(methylamino)-2-oxoethoxy]benzyl]-2-methylnonanamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000004
(2R,4S,5S,7S)-5-amino-N-butyl-7-[3-(2-ethoxyethoxy)-4-methoxybenzyl]-4-hydroxy-2,8-dimethylnonanamide
Homo sapiens
-
pH 7.2, 37°C, purified enzyme
0.000003
(2R,4S,5S,7S)-5-amino-N-butyl-7-[3-(3-ethoxypropoxy)-4-methoxybenzyl]-4-hydroxy-2,8-dimethylnonanamide
Homo sapiens
-
pH 7.2, 37°C, purified enzyme
0.000005
(2R,4S,5S,7S)-5-amino-N-butyl-7-[3-[2,2-dimethyl-3-(methylamino)-3-oxopropoxy]-4-methoxybenzyl]-4-hydroxy-2-methylnonanamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000002
(2R,4S,5S,7S)-5-amino-N-[2-(1,1-dioxidothiomorpholin-4-yl)ethyl]-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2,8-dimethylnonanamide
Homo sapiens
-
pH 7.2, 37°C, purified enzyme
0.000018
(2R,4S,5S,7S)-5-amino-N-[2-(dimethylamino)ethyl]-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2,8-dimethylnonanamide
Homo sapiens
-
pH 7.2, 37°C, purified enzyme
0.000018
(2R,4S,5S,7S)-5-amino-N-[2-(dimethylamino)ethyl]-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2-methylnonanamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000002
(2R,4S,5S,7S)-5-amino-N-[2-(dimethylsulfamoyl)ethyl]-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2,8-dimethylnonanamide
Homo sapiens
-
pH 7.2, 37°C, purified enzyme
0.000004
(2R,4S,5S,7S)-5-amino-N-[2-(ethylsulfonyl)ethyl]-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2,8-dimethylnonanamide
Homo sapiens
-
pH 7.2, 37°C, purified enzyme
0.000006
(2R,4S,5S,7S)-5-amino-N-[2-(tert-butylsulfonyl)ethyl]-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2,8-dimethylnonanamide
Homo sapiens
-
pH 7.2, 37°C, purified enzyme
0.000002
(2R,4S,5S,7S)-5-amino-N-[2-[(2R,6S)-2,6-dimethylmorpholin-4-yl]ethyl]-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2,8-dimethylnonanamide
Homo sapiens
-
pH 7.2, 37°C, purified enzyme
0.0000003
(2R,4S,5S,7S)-N-[2-(acetylamino)ethyl]-5-amino-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2,8-dimethylnonanamide
Homo sapiens
-
pH 7.2, 37°C, purified enzyme
0.000007
(2S,4S,5S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-6-[[4-methoxy-3-(3-methoxypropoxy)benzyl](propan-2-yl)amino]-2-(propan-2-yl)hexanamide
Homo sapiens
-
at pH 7.4, temperature not specified in the publication
0.000016
(2S,4S,5S,7S)-5-amino-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-N-[2-methyl-1-(morpholin-4-yl)propan-2-yl]-2-(propan-2-yl)nonanamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000001
(2S,4S,5S,7S)-5-amino-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-N-[2-methyl-3-(methylamino)-3-oxopropyl]-2-(propan-2-yl)nonanamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0000008
(2S,4S,5S,7S)-5-amino-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-N-[4-(methylamino)-4-oxobutyl]-2-(propan-2-yl)nonanamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000004
(2S,4S,5S,7S)-5-amino-N-(1-amino-1-oxopropan-2-yl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2-(propan-2-yl)nonanamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000013
(2S,4S,5S,7S)-5-amino-N-(1-amino-2-methyl-1-oxopropan-2-yl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2-(propan-2-yl)nonanamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000002
(2S,4S,5S,7S)-5-amino-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2-(propan-2-yl)nonanamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000003
(2S,4S,5S,7S)-5-amino-N-(2-amino-2-oxoethyl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2-(propan-2-yl)nonanamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0000006
(2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2-(propan-2-yl)nonanamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0000009
(2S,4S,5S,7S)-5-amino-N-(3-amino-2-methyl-3-oxopropyl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2-(propan-2-yl)nonanamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000006
(2S,4S,5S,7S)-5-amino-N-(4-amino-4-oxobutan-2-yl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2-(propan-2-yl)nonanamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0000007
(2S,4S,5S,7S)-5-amino-N-(4-amino-4-oxobutyl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2-(propan-2-yl)nonanamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0000004
(2S,4S,5S,7S)-5-amino-N-[2,2-dimethyl-3-(methylamino)-3-oxopropyl]-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2-(propan-2-yl)nonanamide
Homo sapiens
-
pH and temperature not specified in the publication
0.00000055
(5R)-3-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-N-cyclopropyl-N-(2,3-dichlorobenzyl)-8-azabicyclo[3.2.1]oct-2-ene-2-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0000011
(5R)-3-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-N-cyclopropyl-N-(2,3-dichlorobenzyl)-9-azabicyclo[3.3.1]non-2-ene-2-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.00000074
(5R)-3-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-N-cyclopropyl-N-(3-methoxy-2-methylbenzyl)-8-azabicyclo[3.2.1]oct-2-ene-2-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.00000092
(5R)-3-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-N-cyclopropyl-N-(3-methoxy-2-methylbenzyl)-9-azabicyclo[3.3.1]non-2-ene-2-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0194
2'-O-beta-D-glucopyranosyl momordin Ic
Homo sapiens
-
in 50 mM sodium phosphate, pH 6.5, 0.1 M NaCl, 0.02% (v/v) Tween 20, at 37°C
0.0384
2'-O-beta-D-glucopyranosyl momordin IIc
Homo sapiens
-
in 50 mM sodium phosphate, pH 6.5, 0.1 M NaCl, 0.02% (v/v) Tween 20, at 37°C
0.0000019
2-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]benzyl]-N-cyclopropyl-N-(2,3-dichlorobenzyl)-3-(methylamino)propanamide
Homo sapiens
-
at pH 7.4 and 37°C
0.00026
3-(benzylamino)-2-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]benzyl]-N-cyclopropyl-N-(2,3-dichlorobenzyl)propanamide
Homo sapiens
-
at pH 7.4 and 37°C
0.00021
3-amino-2-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]benzyl]-N-cyclopropyl-N-(2,3-dichlorobenzyl)-2-methylpropanamide
Homo sapiens
-
at pH 7.4 and 37°C
0.00000079
3-amino-2-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]benzyl]-N-cyclopropyl-N-(2,3-dichlorobenzyl)propanamide
Homo sapiens
-
at pH 7.4 and 37°C
0.0000004
3-amino-N-cyclopropyl-N-(2,3-dichlorobenzyl)-2-[4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl]propanamide
Homo sapiens
-
at pH 7.4 and 37°C
0.00000026
3-amino-N-cyclopropyl-N-[2,3-dichloro-5-(3-methoxypropyl)benzyl]-2-[4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl]propanamide
Homo sapiens
-
at pH 7.4 and 37°C
0.00000027
3-amino-N-[2-chloro-5-(2-cyanoethyl)benzyl]-N-cyclopropyl-2-[4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl]propanamide
Homo sapiens
-
at pH 7.4 and 37°C
0.00000011
3-amino-N-[2-chloro-5-(3-cyanopropyl)benzyl]-N-cyclopropyl-2-[4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl]propanamide
Homo sapiens
-
at pH 7.4 and 37°C
0.00000009
3-amino-N-[2-chloro-5-(3-hydroxypropyl)benzyl]-N-cyclopropyl-2-[4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl]propanamide
Homo sapiens
-
at pH 7.4 and 37°C
0.00000021
3-amino-N-[2-chloro-5-(4-methoxybutoxy)benzyl]-N-cyclopropyl-2-[4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl]propanamide
Homo sapiens
-
at pH 7.4 and 37°C
0.00000019
3-amino-N-[2-chloro-5-(4-methoxybutyl)benzyl]-N-cyclopropyl-2-[4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl]propanamide
Homo sapiens
-
at pH 7.4 and 37°C
0.00000026
3-amino-N-[2-chloro-5-(6-methoxyhexyl)benzyl]-N-cyclopropyl-2-[4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl]propanamide
Homo sapiens
-
at pH 7.4 and 37°C
0.0000015
3-amino-N-[2-chloro-5-[3-(dimethylamino)propyl]benzyl]-N-cyclopropyl-2-[4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl]propanamide
Homo sapiens
-
at pH 7.4 and 37°C
0.0000003
3-amino-N-[[5-chloro-2-(3-methoxypropyl)-1-oxidopyridin-4-yl]methyl]-N-cyclopropyl-2-[4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl]propanamide
Homo sapiens
-
at pH 7.4 and 37°C
0.00000019
3-amino-N-[[5-chloro-2-(3-methoxypropyl)pyridin-4-yl]methyl]-N-cyclopropyl-2-[4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl]propanamide
Homo sapiens
-
at pH 7.4 and 37°C
0.000003
4-([(2R,4S,5S,7S)-5-amino-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2,8-dimethylnonanoyl]amino)butanoic acid
Homo sapiens
-
pH 7.2, 37°C, purified enzyme
0.000006
4-([(2R,4S,5S,7S)-5-amino-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2,8-dimethylnonanoyl]amino)butyl acetate
Homo sapiens
-
pH 7.2, 37°C, purified enzyme
0.000003
4-([(2R,4S,5S,7S)-5-amino-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2-methylnonanoyl]amino)butanoic acid
Homo sapiens
-
pH and temperature not specified in the publication
0.000006
4-([(2R,4S,5S,7S)-5-amino-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2-methylnonanoyl]amino)butyl acetate
Homo sapiens
-
pH and temperature not specified in the publication
0.000336
4-amino-N-[2-[2-([2-amino-6-ethyl-5-[4-(3-methoxypropyl)-2,2-dimethyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl]pyrimidin-4-yl]amino)ethyl]phenyl]-3-methoxybenzamide
Homo sapiens
-
-
0.00033
4-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-N-cyclopropyl-5,5-difluoro-N-(3-methoxy-2-methylbenzyl)-1,2,5,6-tetrahydropyridine-3-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0000012
4-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-N-cyclopropyl-N-(2,3-dichlorobenzyl)-1,2,5,6-tetrahydropyridine-3-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0008
4-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-N-cyclopropyl-N-(2,3-dichlorobenzyl)-5,5-difluoro-1,2,5,6-tetrahydropyridine-3-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000031
4-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-N-cyclopropyl-N-(2,3-dichlorobenzyl)-5,5-dimethyl-1,2,5,6-tetrahydropyridine-3-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000002
4-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-N-cyclopropyl-N-(3-methoxy-2-methylbenzyl)-1,2,5,6-tetrahydropyridine-3-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.00017
4-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-N-cyclopropyl-N-(3-methoxy-2-methylbenzyl)-5,5-dimethyl-1,2,5,6-tetrahydropyridine-3-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.00065
5-amino-3-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-N-cyclopropyl-N-(2,3-dichlorobenzyl)pentanamide
Homo sapiens
-
at pH 7.4 and 37°C
0.00656
5-[4-[(3,5-difluorobenzyl)amino]phenyl]-6-ethylpyrimidine-2,4-diamine
Homo sapiens
-
-
0.0000071
6-(2,4-diamino-6-ethylpyrimidin-5-yl)-2-(3,5-difluorophenyl)-4-(3-methoxypropyl)-2-methyl-2H-1,4-benzoxazin-3(4H)-one
Homo sapiens
-
-
0.000095
6-(2,4-diamino-6-ethylpyrimidin-5-yl)-2-(3,5-difluorophenyl)-4-(3-methoxypropyl)-2H-1,4-benzoxazin-3(4H)-one
Homo sapiens
-
-
0.000691
6-ethyl-5-[1-(3-methoxypropyl)-1,2,3,4-tetrahydroquinolin-7-yl]pyrimidine-2,4-diamine
Homo sapiens
-
-
0.000058
6-ethyl-5-[1-(3-methoxypropyl)-2-phenyl-1,2,3,4-tetrahydroquinolin-7-yl]pyrimidine-2,4-diamine
Homo sapiens
-
-
0.000173
6-ethyl-5-[9-(3-methoxypropyl)-9H-carbazol-2-yl]pyrimidine-2,4-diamine
Homo sapiens
-
-
0.000034
8-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-N-cyclopropyl-N-(2,3-dichlorobenzyl)-5-azaspiro[2.5]oct-7-ene-7-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.00021
8-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-N-cyclopropyl-N-(3-methoxy-2-methylbenzyl)-5-azaspiro[2.5]oct-7-ene-7-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0000006
aliskiren
0.0000033
BW-175
Homo sapiens
-
temperature not specified in the publication, at pH 7.4
0.000001
CGP-29,287
Homo sapiens
-
temperature not specified in the publication, at pH 7.4
0.0000003
CGP-44099A
Homo sapiens
-
temperature not specified in the publication, at pH 7.4
0.0000007
CGP38560A
Homo sapiens
-
-
0.0774
chikusetsusaponin IV
Homo sapiens
-
in 50 mM sodium phosphate, pH 6.5, 0.1 M NaCl, 0.02% (v/v) Tween 20, at 37°C
0.00000058
CI-992
Homo sapiens
-
temperature not specified in the publication, at pH 7.4
0.000005
CP-72,647
Homo sapiens
-
temperature not specified in the publication, at pH 7.4
0.00001
CP-81,198
Homo sapiens
-
temperature not specified in the publication, at pH 7.4
0.000005
CP-81,282
Homo sapiens
-
temperature not specified in the publication, at pH 7.4
0.273
decanoyl acetal sodium sulfite
Homo sapiens
-
IC50: 0.273 mM
0.0000004
ditekren
Homo sapiens
-
temperature not specified in the publication, at pH 7.4
0.195
dodecanoyl acetal sodium sulfite
Homo sapiens
-
IC50: 0.195 mM
0.000014
enalkiren
Homo sapiens
-
-
0.0000073
ES 6864
Homo sapiens
-
temperature not specified in the publication, at pH 7.4
0.0000007
ES-8891
Homo sapiens
-
temperature not specified in the publication, at pH 7.4
0.000004
ethyl N-[(2R,4S,5S,7S)-5-amino-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2,8-dimethylnonanoyl]-beta-alaninate
Homo sapiens
-
pH 7.2, 37°C, purified enzyme
0.000004
ethyl N-[(2R,4S,5S,7S)-5-amino-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2-methylnonanoyl]-beta-alaninate
Homo sapiens
-
pH and temperature not specified in the publication
0.0000006
FK906
Homo sapiens
-
temperature not specified in the publication, at pH 7.4
0.0571
glycyrrhizin
Homo sapiens
-
in 50 mM sodium phosphate, pH 6.5, 0.1 M NaCl, 0.02% (v/v) Tween 20, at 37°C
0.0000069
GR 70982
Homo sapiens
-
temperature not specified in the publication, at pH 7.4
0.00001
H-141
Homo sapiens
-
temperature not specified in the publication, at pH 7.4
-
0.000001
H-77
Homo sapiens
-
temperature not specified in the publication, at pH 7.4
0.0000006
KR1-1314
Homo sapiens
-
temperature not specified in the publication, at pH 7.4
-
2.3
L-Ile-L-Trp
Homo sapiens
-
recombinant enzyme, in 50 mM Tris-HCl buffer containing 100 mM NaCl (pH 8.0), at 37°C
0.000003
methyl (5-[[(2S,3S,5R)-2-amino-6-(butylamino)-3-hydroxy-5-methyl-6-oxohexyl](propan-2-yl)carbamoyl]-2-methoxybenzyl)carbamate
Homo sapiens
-
at pH 7.4, temperature not specified in the publication
0.000001
methyl 4-([(2R,4S,5S,7S)-5-amino-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2,8-dimethylnonanoyl]amino)butanoate
Homo sapiens
-
pH 7.2, 37°C, purified enzyme
0.0001
methyl [2-(5-[[(2S,3S,5R)-2-amino-6-(butylamino)-3-hydroxy-5-methyl-6-oxohexyl](propan-2-yl)carbamoyl]-2-methoxyphenyl)ethyl]carbamate
Homo sapiens
-
at pH 7.4, temperature not specified in the publication
0.00005
methyl [5-[(2S,4S,5S,7R)-4-amino-8-(butylamino)-2-ethyl-5-hydroxy-7-methyl-8-oxooctyl]-2-methoxyphenoxy]methanesulfinate
Homo sapiens
-
pH and temperature not specified in the publication
0.000006
methyl [5-[(2S,4S,5S,7R)-4-amino-8-(butylamino)-2-ethyl-5-hydroxy-7-methyl-8-oxooctyl]-2-tert-butylphenoxy]acetate
Homo sapiens
-
pH and temperature not specified in the publication
0.000013
methyl [5-[(2S,4S,5S,7R)-4-amino-8-(butylamino)-2-ethyl-5-hydroxy-7-methyl-8-oxooctyl]-2-tert-butylphenoxy]methanesulfinate
Homo sapiens
-
pH and temperature not specified in the publication
0.000004
methyl [5-[(2S,4S,5S,7R)-4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-2-methoxyphenoxy]acetate
Homo sapiens
-
pH 7.2, 37°C, purified enzyme
0.0259
momordin Ic
Homo sapiens
-
in 50 mM sodium phosphate, pH 6.5, 0.1 M NaCl, 0.02% (v/v) Tween 20, at 37°C
0.0468
momordin IIc
Homo sapiens
-
in 50 mM sodium phosphate, pH 6.5, 0.1 M NaCl, 0.02% (v/v) Tween 20, at 37°C
0.0422
monoglucuronyl glycyrrhetic acid
Homo sapiens
-
in 50 mM sodium phosphate, pH 6.5, 0.1 M NaCl, 0.02% (v/v) Tween 20, at 37°C
0.0000029
N-(5-[[acetyl(methyl)amino]methyl]-2-chlorobenzyl)-3-amino-N-cyclopropyl-2-[4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl]propanamide
Homo sapiens
-
at pH 7.4 and 37°C
0.000012
N-[(2R,4S,5S,7S)-5-amino-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2,8-dimethylnonanoyl]-beta-alanine
Homo sapiens
-
pH 7.2, 37°C, purified enzyme
0.000012
N-[(2R,4S,5S,7S)-5-amino-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2-methylnonanoyl]-beta-alanine
Homo sapiens
-
pH and temperature not specified in the publication
0.000008
N-[(2S,3S,5R)-2-amino-6-(butylamino)-3-hydroxy-5-methyl-6-oxohexyl]-3-(3-methoxypropoxy)-4-methyl-N-(propan-2-yl)benzamide
Homo sapiens
-
at pH 7.4, temperature not specified in the publication
0.000008
N-[(2S,3S,5R)-2-amino-6-(butylamino)-3-hydroxy-5-methyl-6-oxohexyl]-4-bromo-3-(3-methoxypropoxy)-N-(propan-2-yl)benzamide
Homo sapiens
-
at pH 7.4, temperature not specified in the publication
0.000002
N-[(2S,3S,5R)-2-amino-6-(butylamino)-3-hydroxy-5-methyl-6-oxohexyl]-4-ethyl-3-(3-methoxypropoxy)-N-(propan-2-yl)benzamide
Homo sapiens
-
at pH 7.4, temperature not specified in the publication
0.000006
N-[(2S,3S,5R)-2-amino-6-(butylamino)-3-hydroxy-5-methyl-6-oxohexyl]-4-ethynyl-3-(3-methoxypropoxy)-N-(propan-2-yl)benzamide
Homo sapiens
-
at pH 7.4, temperature not specified in the publication
0.000002
N-[(2S,3S,5R)-2-amino-6-(butylamino)-3-hydroxy-5-methyl-6-oxohexyl]-4-methoxy-3-(3-methoxypropoxy)-N-(propan-2-yl)benzamide
Homo sapiens
-
at pH 7.4, temperature not specified in the publication
0.000001
N-[(2S,3S,5R)-2-amino-6-(butylamino)-3-hydroxy-5-methyl-6-oxohexyl]-4-methoxy-3-(4-methoxybutyl)-N-(propan-2-yl)benzamide
Homo sapiens
-
at pH 7.4, temperature not specified in the publication
0.000001
N-[(2S,3S,5R)-2-amino-6-(butylamino)-3-hydroxy-5-methyl-6-oxohexyl]-4-methoxy-3-[(1E)-4-methoxybut-1-en-1-yl]-N-(propan-2-yl)benzamide
Homo sapiens
-
at pH 7.4, temperature not specified in the publication
0.000001
N-[(2S,3S,5S)-2-amino-5-(butylcarbamoyl)-3-hydroxy-6-methylheptyl]-4-ethyl-3-(3-methoxypropoxy)-N-(propan-2-yl)benzamide
Homo sapiens
-
at pH 7.4, temperature not specified in the publication
0.000027
N-[2-([2-amino-6-ethyl-5-[4-(3-methoxypropyl)-2,2-dimethyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl]pyrimidin-4-yl]amino)ethyl]naphthalene-2-sulfonamide
Homo sapiens
-
-
0.000222
N-[2-[6-(2,4-diamino-6-ethylpyrimidin-5-yl)-2,2-dimethyl-3-oxo-2,3-dihydro-4H-1,4-benzoxazin-4-yl]ethyl]acetamide
Homo sapiens
-
-
0.0000001
PD 133,450
Homo sapiens
-
temperature not specified in the publication, at pH 7.4
0.0000008
remikiren
Homo sapiens
-
-
0.0000005
Ro 42-5892
Homo sapiens
-
temperature not specified in the publication, at pH 7.4
0.0336
soyasaponin I
Homo sapiens
-
in 50 mM sodium phosphate, pH 6.5, 0.1 M NaCl, 0.02% (v/v) Tween 20, at 37°C
0.0303
soyasaponin II
Homo sapiens
-
in 50 mM sodium phosphate, pH 6.5, 0.1 M NaCl, 0.02% (v/v) Tween 20, at 37°C
-
0.00000035
SQ 33800
Homo sapiens
-
temperature not specified in the publication, at pH 7.4
0.0000001
SR 43845
Homo sapiens
-
temperature not specified in the publication, at pH 7.4
0.0000011
terlakiren
Homo sapiens
-
temperature not specified in the publication, at pH 7.4
0.044
tetradecanoyl acetal sodium sulfite
Homo sapiens
-
complex formation with the enzyme, mixed inhibition type, IC50: 0.044 mM
0.00000047
YM-21095
Homo sapiens
-
temperature not specified in the publication, at pH 7.4
0.0000029
YM-26365
Homo sapiens
-
temperature not specified in the publication, at pH 7.4
0.0000011
zankiren
Homo sapiens
-
-
additional information
aliskiren
SPECIFIC ACTIVITY [µmol/min/mg]
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
additional information
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
5.5 - 6.8
-
-
6 - 7.5
-
-
8
-
assay at
additional information
-
-
pH RANGE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
5
-
no activity below
6 - 8.5
-
more than 30% activity
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
37
-
assay at
ORGANISM
COMMENTARY hide
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
SOURCE
-
placental
Manually annotated by BRENDA team
-
from recombinant expression
Manually annotated by BRENDA team
lymphangioleiomyomatosis cell
Manually annotated by BRENDA team
lymphangioleiomyomatosis nodule, i.e. LAM nodule
Manually annotated by BRENDA team
-
placental
Manually annotated by BRENDA team
additional information
-
not in cerebrospinal fluid
Manually annotated by BRENDA team
LOCALIZATION
ORGANISM
UNIPROT
COMMENTARY hide
GeneOntology No.
LITERATURE
SOURCE
-
renin is stored in secretory granules and is released in response to decreases in renal perfusion pressure, decreases in Cl- in the distal tubule fluid or increased sympathetic nerve stimulation via beta1-adrenoceptors
Manually annotated by BRENDA team
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
metabolism
-
renin is the first rate-limiting enzymatic step in the renin-angiotensin-aldosterone system pathway
physiological function
UNIPROT
ENTRY NAME
ORGANISM
NO. OF AA
NO. OF TRANSM. HELICES
MOLECULAR WEIGHT[Da]
SOURCE
SEQUENCE
LOCALIZATION PREDICTION?
RENI_HUMAN
406
0
45057
Swiss-Prot
Secretory Pathway (Reliability: 2)
PDB
SCOP
CATH
UNIPROT
ORGANISM
MOLECULAR WEIGHT
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
31000 - 44000
41000
-
non-denaturing SDS-PAGE
42000
44000
-
gel filtration, renal active renin
45000 - 59000
46000
-
gel filtration, plasma active renin
48000
-
gel filtration, plasma inactive renin
additional information
SUBUNIT
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
monomer
POSTTRANSLATIONAL MODIFICATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
glycoprotein
-
glycoprotein
-
-
proteolytic modification
-
the inactive prorenin needs to be proteolytically activated to the mature active renin
side-chain modification
-
glycoprotein
CRYSTALLIZATION (Commentary)
ORGANISM
UNIPROT
LITERATURE
in complex with angiotensinogen, sitting drop vapor diffusion method, using 1.74 M (NH4)2SO4 and 0.1 M Tris, pH 7.6
in complex with the (+)- and (-)-enantiomer of inhibitor 7-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-N-cyclopropyl-N-(2,3-dichlorobenzyl)-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxamide. The hydrophobic interactions dominate the positioning of the inhibitors with the pseudosymmetry of the central template being able to establish the necessary hydrogen bonds in either orientation. Substitution of either of the two nitrogen atoms abolishes this pseudosymmetry and completely abrogates this observed effect
hanging drop vapor diffusion method, recombinant renin. Crystal structure of recombinant renin in complex with 5-[4-[(3,5-difluorobenzyl)amino]phenyl]-6-ethylpyrimidine-2,4-diamine, 6-ethyl-5-[1-(3-methoxypropyl)-2-phenyl-1,2,3,4-tetrahydroquinolin-7-yl]pyrimidine-2,4-diamine, and N-[2-([2-amino-6-ethyl-5-[4-(3-methoxypropyl)-2,2-dimethyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl]pyrimidin-4-yl]amino)ethyl]naphthalene-2-sulfonamide
-
modeling of stereo structure of the complex of human renin with dipeptide YY. The loss of inhibitory activiy at basic pH values may be due to a local shift of YY from the center of the renin cleft into the N-domain side
-
PROTEIN VARIANTS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
D226A
inactive
GENERAL STABILITY
ORGANISM
UNIPROT
LITERATURE
bovine serum albumin, stabilization
-
dilution below 1 mg/ml, inactivation
-
freezing/thawing, inactivation
-
STORAGE STABILITY
ORGANISM
UNIPROT
LITERATURE
-20°C, 0.02 M sodium phosphate buffer, pH 6.2, 0.025 M NaCl, 6 months, 90% activity
-
-70°C, 1 mg/ml protein, at least 1 year
-
-70°C, or -20°C, or 4°C, neutral pH
-
-90°C, or -10°C, 10 months
-
0.02M potassium phosphate buffer, pH 7.5, 1 year
-
4°C, inactive renin, 0.1 M phosphate buffer, 1 week
-
PURIFICATION (Commentary)
ORGANISM
UNIPROT
LITERATURE
Superdex S200 gel filtration
2 forms
-
3 forms
-
ammonium sulfate precipitation and Resource S column chromatography
-
inactive renin, activated by trypsin
-
prorenin
-
recombinant renin
-
CLONED (Commentary)
ORGANISM
UNIPROT
LITERATURE
expressed in CHO cells
-
expression in CHO cells
-
expression in COS cells
-
expression in Cos-1 cells
-
expression in DAMP cells
-
expression in human kidney cell line 293
-
expression in Sf9/baculovirus cells
-
expression in transgenic mice
-
EXPRESSION
ORGANISM
UNIPROT
LITERATURE
angiotensin II inhibits renin release from the juxtaglomerular cells in the kidney
-
angiotensin II inhibits the release of renin from the kidney
-
diuretics increase plasma renin concentration and plasma renin activity, as volume depletion stimulates the release of renin from the kidney
-
renin inhibitors like aliskiren increase the plasma concentration of renin because they attenuate the negative feedback effect of angiotensin II on renin release
-
renin-angiotensin-aldosterone system blockade with angiotensin-converting enzyme inhibitors and/or angiotensin receptor blockers leads to exacerbated renin release through loss of negative-feedback inhibition
-
the angiotensin type I receptor 1166C allele in homozygous form is characterized by low plasma renin levels
-
treatment with 16 mg azelnidipine for 4 weeks does not affect plasma renin activity
-
APPLICATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
diagnostics
medicine
pharmacology
REF.
AUTHORS
TITLE
JOURNAL
VOL.
PAGES
YEAR
ORGANISM (UNIPROT)
PUBMED ID
SOURCE
Liu, C.F.; Fehrentz, J.A.; Heitz, A.; LeNguyen, D.; Castro, B.; Heitz, F.; Carelli, C.; Galen, F.X.; Corval, P.
Synthesis, conformation, and antibody recognition of peptides built of the sequence of the flap of human renin
Tetrahedron
44
675-683
1988
Homo sapiens
-
Manually annotated by BRENDA team
Fehrentz, J.A.; Heitz, A.; Seyer, R.; Fulcrand, P.; Devilliers, R.; Castro, B.; Heitz, F.; Carelli, C.
Peptides mimicking the flap of human renin: Synthesis, conformation, and antibody recognition
Biochemistry
27
4071-4078
1988
Homo sapiens
Manually annotated by BRENDA team
Egan, D.A.; Grzegorczyk, V.; Tricarico, K.A.; Rueter, A.; Hollemann, W.H.; Marcotte, P.A.
Human placental chorionic renin: Production, purification and characterization
Biochim. Biophys. Acta
965
68-75
1988
Homo sapiens
Manually annotated by BRENDA team
Tong, L.; Pav, S.; Lamarre, D.; Pilote, L.; LaPlante, S.; Anderson, P.C.; Jung, G.
High resolution crystal structure of recombinant human renin in complex with polyhydroxymonoamide inhibitors
J. Mol. Biol.
250
211-222
1995
Homo sapiens
Manually annotated by BRENDA team
Shinagawa, T.; Do, Y.S.; Tam, H.; Hsueh, W.A.
Complete purification of human renal renin and sequence of the amino terminus
Biochem. Biophys. Res. Commun.
139
446-454
1986
Homo sapiens
Manually annotated by BRENDA team
Kim, S.J.; Hirose, S.; Murakami, K.
Purification of human plasma inactive renin by immunoaffinity chromatography on profragment-specific IgG
Biochim. Biophys. Acta
873
27-30
1986
Homo sapiens
Manually annotated by BRENDA team
Hemmings, A.M.; Foundling, S.I.; Sibanda, B.L.; Wood, S.P.; Pearl, L.H.; Blundell, T.
Energy calculations on aspartic proteinases: Human renin, endotiapepsin and its complex with an angiotensinogen fragment analogue, H-142
Biochem. Soc. Trans.
13
1036-1041
1985
Homo sapiens
Manually annotated by BRENDA team
Leckie, B.J.
Human renin inhibitors
Aspartic Proteinases and their Inhibitors, Proc. FEBS Adv. Course, Meeting Date 1984 (Kostka, V. , ed. ), de Gruyter, Berlin, New York
443-461
1985
Homo sapiens
-
Manually annotated by BRENDA team
Leckie, B.J.; Szelke, M.; Atrash, B.; Beattie, S.R.; Hallett, A.; Jones, D.M.; McIntyre, G.D.; Suerias, J.; Webb, D.J.
Human renin inhibitors
Biochem. Soc. Trans.
13
1029-1032
1985
Homo sapiens
Manually annotated by BRENDA team
Szelke, M.
Chemistry of renin inhibitors
Aspartic Proteinases and their Inhibitors, Proc. FEBS Adv. Course, Meeting Date 1984 (Kostka, V. , ed. ), de Gruyter, Berlin, New York
421-441
1985
Homo sapiens
-
Manually annotated by BRENDA team
Inagami, T.; Misono, K.; Chang, J.J.; Takii, Y.; Dykes, C.
Renin and general aspartyl proteases: Differences and similarities in structure and function
Aspartic Proteinases and their Inhibitors, Proc. FEBS Adv. Course, Meeting Date 1984 (Kostka, V. , ed. ), de Gruyter, Berlin, New York
318-337
1985
Homo sapiens
-
Manually annotated by BRENDA team
Inagami, T.; Misono, K.S.; Chang, J.J.; Takii, Y.
Biochemistry of renin
Biochem. Soc. Trans.
12
951-953
1984
Homo sapiens, Mus musculus
Manually annotated by BRENDA team
Tree, M.; Brown, J.J.; Leckie, B.J.; Lever, A.F.; Manthem, P.; Morton, J.J.; Robertson, J.I.; Szelke, M.; Webb, D.
The renin-angiotensin converting enzyme cascade
Biochem. Soc. Trans.
12
948-951
1984
Canis lupus familiaris, Equus caballus, Homo sapiens, Rattus norvegicus, Sus scrofa
-
Manually annotated by BRENDA team
Ganong, W.F.
The brain renin-angiotensin system
Annu. Rev. Physiol.
46
17-31
1984
Homo sapiens, Rattus norvegicus
Manually annotated by BRENDA team
Norman, J.A.; Hadjilambris, O.; Baska, R.; Sharp, D.Y.; Kumar, R.
Stable expression, secretion, and characterization of active human renin in mammalian cells
Mol. Pharmacol.
41
53-59
1991
Homo sapiens
Manually annotated by BRENDA team
Slater, E.E.
Renin
Methods Enzymol.
80
427-442
1981
Homo sapiens, Mus musculus, Sus scrofa
Manually annotated by BRENDA team
Slater, E.E.; Strout, H.V.
Pure human renin
J. Biol. Chem.
256
8164-8171
1981
Homo sapiens
Manually annotated by BRENDA team
Yokosawa, H.; Holladay, L.A.; Inagami, T.; Haas, E.; Murakami, K.
Human renal renin
J. Biol. Chem.
255
3498-3502
1980
Homo sapiens
Manually annotated by BRENDA team
Takaori, K.; Kim, S.; Fukamizu, A.; Sagara, M.; Hosoi, M.; Katsuki, M.; Murakami, K.; Yamamoto, K.
Biochemical characteristics of human renin expressed in transgenic mice
Clin. Sci.
84
21-29
1993
Homo sapiens
Manually annotated by BRENDA team
Geoghegan, K.F.; Lanzetti, A.J.; Ammirati, M.J.; Danley, D.E.; O'Connor, B.A.; Hobart, P.M.
Simple procedure for recovery of crystallizable human recombinant renin from mammalian cell-conditioned medium
Adv. Exp. Med. Biol.
306
379-381
1991
Homo sapiens
Manually annotated by BRENDA team
Ito, T.; Devaux, C.; Gautray, J.P.; Menard, J.; Corvol, P.
Physicochemical properties of non-activated and activated renin from human amniotic fluid
Biochim. Biophys. Acta
569
202-210
1979
Homo sapiens
Manually annotated by BRENDA team
Galen, F.X.; Devaux, C.; Guyenne, T.; Menard, J.; Corvol, P.
Multiple forms of human renin
J. Biol. Chem.
254
4848-4855
1979
Homo sapiens
Manually annotated by BRENDA team
Morris, B.J.
Properties of the activation by pepsin of inactive renin in human amniotic fluid
Biochim. Biophys. Acta
527
86-97
1978
Homo sapiens
Manually annotated by BRENDA team
Inagami, T.
Structure and function of renin
J. Hypertens.
7
S3-S7
1989
Canis lupus familiaris, Homo sapiens, Mus musculus, Rattus norvegicus, Sus scrofa
Manually annotated by BRENDA team
Evans, D.B.; Cornette, J.C.; Sawyer, T.K.; Staples, D.J.; De Vaux, A.E.; Sharma, S.K.
Substrate specificity and inhibitor structure-activity relationships of recombinant human renin: Implications in the in vivo evaluation of renin inhibitors
Biotechnol. Appl. Biochem.
12
161-175
1990
Homo sapiens
Manually annotated by BRENDA team
Kataoka, K.; Kurokawa, N.; Sawada, M.; Iguchi, K.; Yanaihara, N.; Takahara, S.; Okuyama, A.; Yanaihara, C.
Comparative immunochemical characterization of prorenin/renin in human extrarenal tissues and plasma with use of two specific radioummunoassay systems
Biomed. Res.
16
371-380
1995
Homo sapiens
-
Manually annotated by BRENDA team
Vlahos, C.J.; Walls, J.D.; Berg, D.T.; Grinnel, B.W.
The purification and characterization of recombinant human renin expressed in the human kidney cell line 293
Biochem. Biophys. Res. Commun.
171
375-383
1990
Homo sapiens
Manually annotated by BRENDA team
Pilote, L.; McKercher, G.; Thibeault, D.; Lamarre, D.
Enzymatic characterization of purified recombinant human renin
Biochem. Cell Biol.
73
163-170
1995
Homo sapiens
Manually annotated by BRENDA team
Mathews, S.; Doebli, H.; Pruschy, M.; Bosser, R.; D'Arcy, A.; Oefner, C.; Zulauf, M.; Gentz, R.; Breu, V.; Matile, H.; Schlaeger, J.; Fischli, W.
Recombinant human renin produced in different expression systems: Biochemical properties and 3D structure
Protein Expr. Purif.
7
81-91
1996
Homo sapiens
Manually annotated by BRENDA team
Imai, T.; Miyazaki, H.; Hirose, S.; Hori, H.; Hayashi, T.; Kageyema, R.; Ohkubo, H.; Nakanishi, S.; Murakami, K.
Cloning and sequence analysis of cDNA for human renin precursor
Proc. Natl. Acad. Sci. USA
80
7405
1983
Homo sapiens
Manually annotated by BRENDA team
Sielecki, A.R.; Hayakawa, K.; Fujinaga, M.; Murphy, M.E.P.; Fraser, M.; Muir, S.K.; Carilli, C.T.; Lewicki, J.A.; Baxter, J.D.; James, M.N.G.
Structure of recombinant human renin, a target for carciovascular-active drugs, at 2.5 A resolution
Science
243
1346-1351
1989
Homo sapiens
Manually annotated by BRENDA team
Holzman, T.F.; Chung, C.C.; Edalji, R.; Egan, D.A.; Martin, M.; Gubbins, E.J.; Krafft, G.A.; Wang, G.T.; Thomas, A.M.; Rosenberg, S.H.; Hutchins, C.
Characterization of recombinant human renin: Kinetics, pH-stability, and peptidomimetic inhibitor binding
J. Protein Chem.
10
553-563
1991
Homo sapiens
Manually annotated by BRENDA team
Epps, D.E.; Cheney, J.; Schostarez, H.; Sawyer, T.K.; Prairie, M.; Krueger, W.C.; Mandel, F.
Thermodynamics of the interaction of inhibitors with the binding site of recombinant human renin
J. Med. Chem.
33
2080-2086
1990
Homo sapiens
Manually annotated by BRENDA team
Lefevre, G.; Gauron, S.
Automated quantitative determination of the new renin inhibitor CGP 60536 by high-performance liquid chromatography
J. Chromatogr. B
738
129-136
2000
Homo sapiens
Manually annotated by BRENDA team
Valencia, J.C.; Pacheco-Rodriguez, G.; Carmona, A.K.; Xavier, J.; Bruneval, P.; Riemenschneider, W.K.; Ikeda, Y.; Yu, Z.X.; Ferrans, V.J.; Moss, J.
Tissue-specific renin-angiotensin system in pulmonary lymphangioleiomyomatosis
Am. J. Respir. Cell Mol. Biol.
35
40-47
2006
Homo sapiens (Q8IYK8), Homo sapiens
Manually annotated by BRENDA team
Yuan, L.; Wu, J.; Aluko, R.E.; Ye, X.
Kinetics of renin inhibition by sodium houttuyfonate analogs
Biosci. Biotechnol. Biochem.
70
2275-2280
2006
Homo sapiens
Manually annotated by BRENDA team
Schwartz, G.L.; Turner, S.T.
Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity
Clin. Chem.
51
386-394
2005
Homo sapiens
Manually annotated by BRENDA team
Unger, N.; Lopez Schmidt, I.; Pitt, C.; Walz, M.K.; Philipp, T.; Mann, K.; Petersenn, S.
Comparison of active renin concentration and plasma renin activity for the diagnosis of primary hyperaldosteronism in patients with an adrenal mass
Eur. J. Endocrinol.
150
517-523
2004
Homo sapiens
Manually annotated by BRENDA team
Ferrari, P.; Shaw, S.G.; Nicod, J.; Saner, E.; Nussberger, J.
Active renin versus plasma renin activity to define aldosterone-to-renin ratio for primary aldosteronism
J. Hypertens.
22
377-381
2004
Homo sapiens
Manually annotated by BRENDA team
Cobankara, V.; Oztuerk, M.A.; Kiraz, S.; Ertenli, I.; Haznedaroglu, I.C.; Pay, S.; Calgueneri, M.
Renin and angiotensin-converting enzyme (ACE) as active components of the local synovial renin-angiotensin system in rheumatoid arthritis
Rheumatol. Int.
25
285-291
2005
Homo sapiens
Manually annotated by BRENDA team
Blumenfeld, J.D.
Plasma renin activity for predicting antihypertensive drug efficacy
Am. J. Hypertens.
21
5-6
2008
Homo sapiens
Manually annotated by BRENDA team
Sarver, R.W.; Peevers, J.; Cody, W.L.; Ciske, F.L.; Dyer, J.; Emerson, S.D.; Hagadorn, J.C.; Holsworth, D.D.; Jalaie, M.; Kaufman, M.; Mastronardi, M.; McConnell, P.; Powell, N.A.; Quin, J.; Van Huis, C.A.; Zhang, E.; Mochalkin, I.
Binding thermodynamics of substituted diaminopyrimidine renin inhibitors
Anal. Biochem.
360
30-40
2007
Homo sapiens
Manually annotated by BRENDA team
Nakagawa, T.; Akaki, J.; Satou, R.; Takaya, M.; Iwata, H.; Katsurada, A.; Nishiuchi, K.; Ohmura, Y.; Suzuki, F.; Nakamura, Y.
The His-Pro-Phe motif of angiotensinogen is a crucial determinant of the substrate specificity of renin
Biol. Chem.
388
237-246
2007
Homo sapiens
Manually annotated by BRENDA team
Velloso, E.P.; Vieira, R.; Cabral, A.C.; Kalapothakis, E.; Santos, R.A.
Reduced plasma levels of angiotensin-(1-7) and renin activity in preeclamptic patients are associated with the angiotensin I- converting enzyme deletion/deletion genotype
Braz. J. Med. Biol. Res.
40
583-590
2007
Homo sapiens
Manually annotated by BRENDA team
Tsutamoto, T.; Sakai, H.; Tanaka, T.; Fujii, M.; Yamamoto, T.; Wada, A.; Ohnishi, M.; Horie, M.
Comparison of active renin concentration and plasma renin activity as a prognostic predictor in patients with heart failure
Circ. J.
71
915-921
2007
Homo sapiens
Manually annotated by BRENDA team
Menard, J.; Guyene, T.T.; Peyrard, S.; Azizi, M.
Conformational changes in prorenin during renin inhibition in vitro and in vivo
J. Hypertens.
24
529-534
2006
Homo sapiens
Manually annotated by BRENDA team
Goeschke, R.; Stutz, S.; Rasetti, V.; Cohen, N.C.; Rahuel, J.; Rigollier, P.; Baum, H.P.; Forgiarini, P.; Schnell, C.R.; Wagner, T.; Gruetter, M.G.; Fuhrer, W.; Schilling, W.; Cumin, F.; Wood, J.M.; Maibaum, J.
Novel 2,7-dialkyl-substituted 5(S)-amino-4(S)-hydroxy-8-phenyl-octanecarboxamide transition state peptidomimetics are potent and orally active inhibitors of human renin
J. Med. Chem.
50
4818-4831
2007
Homo sapiens, Callithrix sp.
Manually annotated by BRENDA team
Staessen, J.A.; Li, Y.; Richart, T.
Oral renin inhibitors
Lancet
368
1449-1456
2006
Homo sapiens
Manually annotated by BRENDA team
Pazik, J.; Ostrowska, J.; Lewandowski, Z.; Mroz, A.; Perkowska-Ptasi?ska, A.; Baczkowska, T.; Durlik, M.
Renin-angiotensin-aldosterone system inhibitors and statins prolong graft survival in post-transplant glomerulonephritis
Ann. Transplant.
13
41-45
2008
Homo sapiens
Manually annotated by BRENDA team
Park, P.J.; Ahn, C.B.; Jeon, Y.J.; Je, J.Y.
Renin inhibition activity by chitooligosaccharides
Bioorg. Med. Chem. Lett.
18
2471-2474
2008
Homo sapiens
Manually annotated by BRENDA team
Takahashi, S.; Hori, K.; Shinbo, M.; Hiwatashi, K.; Gotoh, T.; Yamada, S.
Isolation of human renin inhibitor from soybean: soyasaponin I is the novel human renin inhibitor in soybean
Biosci. Biotechnol. Biochem.
72
3232-3236
2008
Homo sapiens
Manually annotated by BRENDA team
Vaidyanathan, S.; Bartlett, M.; Dieterich, H.A.; Yeh, C.M.; Antunes, A.; Howard, D.; Dole, W.P.
Pharmacokinetic interaction of the direct renin inhibitor aliskiren with furosemide and extended-release isosorbide-5-mononitrate in healthy subjects
Cardiovasc. Ther.
26
238-246
2008
Homo sapiens
Manually annotated by BRENDA team
Fisher, N.D.; Jan Danser, A.H.; Nussberger, J.; Dole, W.P.; Hollenberg, N.K.
Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans
Circulation
117
3199-3205
2008
Homo sapiens
Manually annotated by BRENDA team
Hong, Y.; Dingemanse, J.; Mager, D.E.
Pharmacokinetic/pharmacodynamic modeling of renin biomarkers in subjects treated with the renin inhibitor aliskiren
Clin. Pharmacol. Ther.
84
136-143
2008
Homo sapiens
Manually annotated by BRENDA team
Sultana, A.; Nabi, A.H.; Biswas, K.B.; Takemoto, M.; Suzuki, F.
A peptide YY inhibits the human renin activity in a pH dependent manner
Front. Biosci.
14
3286-3291
2009
Homo sapiens
Manually annotated by BRENDA team
Kushiro, T.; Itakura, H.; Abo, Y.; Gotou, H.; Terao, S.; Keefe, D.L.
Long-term safety, tolerability, and antihypertensive efficacy of aliskiren, an oral direct renin inhibitor, in Japanese patients with hypertension
Hypertens. Res.
32
169-175
2009
Homo sapiens
Manually annotated by BRENDA team
Ayalasomayajula, S.; Yeh, C.M.; Vaidyanathan, S.; Flannery, B.; Dieterich, H.A.; Howard, D.; Bedigian, M.P.; Dole, W.P.
Effects of aliskiren, a direct renin inhibitor, on cardiac repolarization and conduction in healthy subjects
J. Clin. Pharmacol.
48
799-811
2008
Homo sapiens
Manually annotated by BRENDA team
Bezencon, O.; Bur, D.; Weller, T.; Richard-Bildstein, S.; Remen, L.; Sifferlen, T.; Corminboeuf, O.; Grisostomi, C.; Boss, C.; Prade, L.; Delahaye, S.; Treiber, A.; Strickner, P.; Binkert, C.; Hess, P.; Steiner, B.; Fischli, W.
Design and preparation of potent, nonpeptidic, bioavailable renin inhibitors (dagger)
J. Med. Chem.
52
3689-3702
2009
Rattus norvegicus, Homo sapiens (P00797)
Manually annotated by BRENDA team
Dietz, R.; Dechend, R.; Yu, C.M.; Bheda, M.; Ford, J.; Prescott, M.F.; Keefe, D.L.
Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension
J. Renin Angiotensin Aldosterone Syst.
9
163-175
2008
Homo sapiens
Manually annotated by BRENDA team
Riccioni, G.; Vitulano, N.; DOrazio, N.; Bellocci, F.
Aliskiren, the first approved renin inhibitor: Clinical application and safety in the treatment of hypertension
Adv. Ther.
26
700-710
2009
Homo sapiens
Manually annotated by BRENDA team
Israili, Z.H.; Velasco, M.; Bermudez, V.
Direct renin inhibitors as antihypertensive agents
Am. J. Ther.
17
237-254
2010
Homo sapiens
Manually annotated by BRENDA team
Takahashi, S.; Hori, K.; Hokari, M.; Gotoh, T.; Sugiyama, T.
Inhibition of human renin activity by saponins
Biomed. Res.
31
155-159
2010
Homo sapiens
Manually annotated by BRENDA team
Tice, C.M.; Xu, Z.; Yuan, J.; Simpson, R.D.; Cacatian, S.T.; Flaherty, P.T.; Zhao, W.; Guo, J.; Ishchenko, A.; Singh, S.B.; Wu, Z.; Scott, B.B.; Bukhtiyarov, Y.; Berbaum, J.; Mason, J.; Panemangalore, R.; Cappiello, M.G.; Mueller, D.; Harrison, R.K.; McGeehan, G.M.; Dillard, L.W.; Baldwin, J.J.; Claremon, D.A.
Design and optimization of renin inhibitors: Orally bioavailable alkyl amines
Bioorg. Med. Chem. Lett.
19
3541-3545
2009
Homo sapiens (P00797)
Manually annotated by BRENDA team
Yamaguchi, Y.; Menear, K.; Cohen, N.C.; Mah, R.; Cumin, F.; Schnell, C.; Wood, J.M.; Maibaum, J.
The P1N-isopropyl motif bearing hydroxyethylene dipeptide isostere analogues of aliskiren are in vitro potent inhibitors of the human aspartyl protease renin
Bioorg. Med. Chem. Lett.
19
4863-4867
2009
Homo sapiens
Manually annotated by BRENDA team
Remen, L.; Bezencon, O.; Richard-Bildstein, S.; Bur, D.; Prade, L.; Corminboeuf, O.; Boss, C.; Grisostomi, C.; Sifferlen, T.; Strickner, P.; Hess, P.; Delahaye, S.; Treiber, A.; Weller, T.; Binkert, C.; Steiner, B.; Fischli, W.
New classes of potent and bioavailable human renin inhibitors
Bioorg. Med. Chem. Lett.
19
6762-6765
2009
Homo sapiens
Manually annotated by BRENDA team
Chen, A.; Bayly, C.; Bezencon, O.; Richard-Bildstein, S.; Dube, D.; Dube, L.; Gagne, S.; Gallant, M.; Gaudreault, M.; Grimm, E.; Houle, R.; Lacombe, P.; Laliberte, S.; Levesque, J.F.; Liu, S.; MacDonald, D.; Mackay, B.; Martin, D.; McKay, D.; Powell, D.; Remen, L.; Soisson, S.; Toulmond, S.
Design and optimization of a substituted amino propanamide series of renin inhibitors for the treatment of hypertension
Bioorg. Med. Chem. Lett.
20
2204-2209
2010
Homo sapiens
Manually annotated by BRENDA team
Xu, Z.; Cacatian, S.; Yuan, J.; Simpson, R.D.; Jia, L.; Zhao, W.; Tice, C.M.; Flaherty, P.T.; Guo, J.; Ishchenko, A.; Singh, S.B.; Wu, Z.; McKeever, B.M.; Scott, B.B.; Bukhtiyarov, Y.; Berbaum, J.; Mason, J.; Panemangalore, R.; Cappiello, M.G.; Bentley, R.; Doe, C.P.; Harrison, R.K.; McGeehan, G.M.; Dillard, L.W.
Optimization of orally bioavailable alkyl amine renin inhibitors
Bioorg. Med. Chem. Lett.
20
694-699
2010
Homo sapiens
Manually annotated by BRENDA team
Mende, C.W.
Application of direct renin inhibition to chronic kidney disease
Cardiovasc. Drugs Ther.
24
139-149
2010
Homo sapiens
Manually annotated by BRENDA team
Schmieder, R.E.; Philipp, T.; Guerediaga, J.; Gorostidi, M.; Smith, B.; Weissbach, N.; Maboudian, M.; Botha, J.; van Ingen, H.
Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide
Circulation
119
417-425
2009
Homo sapiens
Manually annotated by BRENDA team
Solomon, S.D.; Appelbaum, E.; Manning, W.J.; Verma, A.; Berglund, T.; Lukashevich, V.; Cherif Papst, C.; Smith, B.A.; Dahloef, B.; Dahloef, B.
Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy
Circulation
119
530-537
2009
Homo sapiens
Manually annotated by BRENDA team
Puig, J.G.; Schunkert, H.; Taylor, A.A.; Boye, S.; Jin, J.; Keefe, D.L.
Evaluation of the dose--response relationship of aliskiren, a direct renin inhibitor, in an 8-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled study in adult patients with stage 1 or 2 essential hypertension
Clin. Ther.
31
2839-2850
2009
Homo sapiens
Manually annotated by BRENDA team
Komers, R.
What is the role of renin inhibition in the treatment of diabetic kidney disease?
Curr. Diab. Rep.
9
447-452
2009
Homo sapiens
Manually annotated by BRENDA team
Pinto, R.; Gradman, A.H.
Direct renin inhibition: an update
Curr. Hypertens. Rep.
11
456-462
2009
Homo sapiens
Manually annotated by BRENDA team
Duesing, R.; Sellers, F.
ACE inhibitors, angiotensin receptor blockers and direct renin inhibitors in combination: a review of their role after the ONTARGET trial
Curr. Med. Res. Opin.
25
2287-2301
2009
Homo sapiens
Manually annotated by BRENDA team
Moutzouri, E.; Florentin, M.; Elisaf, M.S.; Mikhailidis, D.P.; Liberopoulos, E.N.
Aliskiren, a directrenin inhibitor, in clinical practice: a new approach in the treatment of hypertension
Curr. Vasc. Pharmacol.
8
344-362
2010
Homo sapiens
Manually annotated by BRENDA team
Tapaninen, T.; Neuvonen, P.J.; Niemi, M.
Rifampicin reduces the plasma concentrations and the renin-inhibiting effect of aliskiren
Eur. J. Clin. Pharmacol.
66
497-502
2010
Homo sapiens
Manually annotated by BRENDA team
Tapaninen, T.; Neuvonen, P.J.; Niemi, M.
Effect of ABCB1 haplotypes on the pharmacokinetics and renin-inhibiting effect of aliskiren
Eur. J. Clin. Pharmacol.
66
865-870
2010
Homo sapiens
Manually annotated by BRENDA team
Politi, A.; Durdagi, S.; Moutevelis-Minakakis, P.; Kokotos, G.; Papadopoulos, M.G.; Mavromoustakos, T.
Application of 3D QSAR CoMFA/CoMSIA and in silico docking studies on novel renin inhibitors against cardiovascular diseases
Eur. J. Med. Chem.
44
3703-3711
2009
Homo sapiens
Manually annotated by BRENDA team
Morales-Suarez-Varela, M.M.; Mansego, M.L.; Martin-Escudero, J.C.; Llopis-Gonzalez, A.; Chaves, F.J.; Lopez-Izquierdo, R.; Frutos-Llanes, R.; Vicedo-Cabrera, A.M.
How ineffective hypertension control in subjects treated with angiotensin-converting enzyme inhibitors is related to polymorphisms in the renin-angiotensin-aldosterone system
Eur. J. Pharm. Sci.
39
380-386
2010
Homo sapiens
Manually annotated by BRENDA team
Danser, A.H.
The increase in renin during renin inhibition: does it result in harmful effects by the (pro)renin receptor?
Hypertens. Res.
33
4-10
2010
Homo sapiens
Manually annotated by BRENDA team
Schneider, M.P.; Hua, T.A.; Boehm, M.; Wachtell, K.; Kjeldsen, S.E.; Schmieder, R.E.
Prevention of atrial fibrillation by renin-angiotensin system inhibition a meta-analysis
J. Am. Coll. Cardiol.
55
2299-2307
2010
Homo sapiens
Manually annotated by BRENDA team
Kher, V.
Renin inhibition - benefit beyond hypertension control
J. Assoc. Physicians India
57
518-20, 525
2009
Homo sapiens
Manually annotated by BRENDA team
Hannila-Handelberg, T.; Kontula, K.K.; Paukku, K.; Lehtonen, J.Y.; Virtamo, J.; Tikkanen, I.; Hiltunen, T.P.
Common genetic variations of the renin-angiotensin-aldosterone system and response to acute angiotensin I-converting enzyme inhibition in essential hypertension
J. Hypertens.
28
771-779
2010
Homo sapiens
Manually annotated by BRENDA team
Doulton, T.W.; MacGregor, G.A.
Combination renin-angiotensin system blockade with the renin inhibitor aliskiren in hypertension
J. Renin Angiotensin Aldosterone Syst.
10
185-189
2009
Homo sapiens
Manually annotated by BRENDA team
Sever, P.S.; Gradman, A.H.; Azizi, M.
Managing cardiovascular and renal risk: the potential of direct renin inhibition
J. Renin Angiotensin Aldosterone Syst.
10
65-76
2009
Homo sapiens
Manually annotated by BRENDA team
Ferrario, C.M.
Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin-angiotensin-aldosterone system: antihypertensive effects and benefits beyond BP control
Life Sci.
86
289-299
2010
Homo sapiens
Manually annotated by BRENDA team
Mueller, A.; Schweizer, J.; Kirch, W.; Schindler, C.; Schindler, C.
[Current status of antihypertensive drug treatment in primary care practice at launch of the new renin inhibitor aliskiren (RASANT)]
Med. Klin.
105
155-162
2010
Homo sapiens
Manually annotated by BRENDA team
Hollenberg, N.K.
Direct renin inhibition and the kidney
Nat. Rev. Nephrol.
6
49-55
2010
Homo sapiens
Manually annotated by BRENDA team
Kiski, D.; Stepper, W.; Brand, E.; Breithardt, G.; Reinecke, H.
Impact of renin-angiotensin-aldosterone blockade by angiotensin-converting enzyme inhibitors or AT-1 blockers on frequency of contrast medium-induced nephropathy: a post-hoc analysis from the Dialysis-versus-Diuresis (DVD) trial
Nephrol. Dial. Transplant.
25
759-764
2010
Homo sapiens
Manually annotated by BRENDA team
Jing, S.; Kezhou, Y.; Hong, Z.; Qun, W.; Rong, W.
Effect of renin-angiotensin system inhibitors on prevention of peritoneal fibrosis in peritoneal dialysis patients
Nephrology
15
27-32
2010
Homo sapiens
Manually annotated by BRENDA team
Hanessian, S.; Guesne, S.; Chenard, E.
Total synthesis of "aliskiren": the first renin inhibitor in clinical practice for hypertension
Org. Lett.
12
1816-1819
2010
Homo sapiens
Manually annotated by BRENDA team
Udenigwe, C.; Li, H.; Aluko, R.
Quantitative structure-activity relationship modeling of renin-inhibiting dipeptides
Amino Acids
2011
1-8
2011
Homo sapiens
Manually annotated by BRENDA team
Wedatilake, Y.N.; Scanlon, M.J.; Barnes, S.C.
The clinical utility of two renin mass methods to detect primary hyperaldosteronism compared with renin activity
Ann. Clin. Biochem.
48
256-262
2011
Homo sapiens
Manually annotated by BRENDA team
Bystrom, C.E.; Salameh, W.; Reitz, R.; Clarke, N.J.
Plasma renin activity by LC-MS/MS: development of a prototypical clinical assay reveals a subpopulation of human plasma samples with substantial peptidase activity
Clin. Chem.
56
1561-1569
2010
Homo sapiens
Manually annotated by BRENDA team
Kondo, T.; Goto, R.; Sonoda, K.; Yasuda, T.; Ono, K.; Takaki, Y.; Yatsuda, R.; Miyamura, N.; Araki, E.
Plasma renin activity and aldosterone concentration are not altered by the novel calcium channel antagonist, azelnidipine, in hypertensive patients
Intern. Med.
49
637-643
2010
Homo sapiens
Manually annotated by BRENDA team
Yamashita, S.; Shibata, N.; Boku-Ikeda, A.; Abe, E.; Inayama, A.; Yamaguchi, T.; Higuma, A.; Inagaki, K.; Tsuyuzaki, T.; Iwamoto, S.; Ohno, S.; Yokogawa, T.; Nishikawa, K.; Biswas, K.B.; Nabi, A.H.; Nakagawa, T.; Suzuki, F.; Ebihara, A.
Escherichia coli-based production of recombinant ovine angiotensinogen and its characterization as a renin substrate
BMC Biotechnol.
16
33
2016
Homo sapiens
Manually annotated by BRENDA team
Girgih, A.T.; Nwachukwu, I.D.; Hasan, F.; Fagbemi, T.N.; Gill, T.; Aluko, R.E.
Kinetics of the inhibition of renin and angiotensin I-converting enzyme by cod (Gadus morhua) protein hydrolysates and their antihypertensive effects in spontaneously hypertensive rats
Food Nutr. Res.
59
29788
2015
Homo sapiens
Manually annotated by BRENDA team
Fu, Y.; Alashi, A.M.; Young, J.F.; Therkildsen, M.; Aluko, R.E.
Enzyme inhibition kinetics and molecular interactions of patatin peptides with angiotensin I-converting enzyme and renin
Int. J. Biol. Macromol.
101
207-213
2017
Homo sapiens (P00797)
Manually annotated by BRENDA team
Yan, Y.; Zhou, A.; Carrell, R.W.; Read, R.J.
Structural basis for the specificity of renin-mediated angiotensinogen cleavage
J. Biol. Chem.
294
2353-2364
2019
Homo sapiens (P00797), Homo sapiens
Manually annotated by BRENDA team